Category: Medicine

A groundbreaking blood test could identify dementia risk in women up to 25 years before symptoms appear, according to research from the University of California San Diego.

Researchers from the University of California San Diego have developed a blood test that may determine a woman’s risk of developing dementia as early as 25 years before any symptoms manifest. This promising finding centers on a specific biomarker protein associated with the early pathological processes of Alzheimer’s disease, known as phosphorylated tau 217 (p-tau217).

The study analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study, conducted in the late 1990s. The participants, aged between 65 and 79, exhibited no signs of cognitive decline at the study’s outset. Over a follow-up period of up to 25 years, researchers found a strong association between elevated levels of p-tau217 and future instances of mild cognitive impairment and dementia.

Women with higher levels of p-tau217 at the beginning of the study were significantly more likely to develop dementia later on. The findings were published in JAMA Network Open, highlighting the potential for early detection of dementia risk through a simple blood test.

“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” said Aladdin H. Shadyab, the study’s first author and an associate professor of public health and medicine at UC San Diego. “Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin.”

This early detection could pave the way for preventive strategies and targeted monitoring, allowing for interventions before memory issues disrupt daily life. Shadyab emphasized that as research progresses, these biomarkers could help pinpoint individuals at the greatest risk and inform strategies to delay or prevent dementia.

However, the relationship between p-tau217 levels and dementia risk was not uniform across all demographics. The study indicated that women over 70 with elevated p-tau217 levels experienced poorer cognitive outcomes compared to their younger counterparts. Additionally, those with the APOE ε4 gene, a known risk factor for Alzheimer’s disease, also showed a stronger correlation between p-tau217 levels and cognitive decline.

Interestingly, the study revealed that p-tau217 was a more significant predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy, compared to those who received a placebo. This finding suggests that hormonal factors may play a role in the relationship between p-tau217 levels and dementia risk.

Senior author Linda K. McEvoy, a senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, noted the advantages of blood-based biomarkers like p-tau217. “Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” she explained. “This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”

Despite the promising nature of these findings, Shadyab cautioned that blood tests for Alzheimer’s disease are still under investigation and are not yet recommended for routine screening in asymptomatic individuals. Further research is necessary before this approach can be considered for clinical use prior to the onset of cognitive symptoms.

Future studies should explore how various factors, including genetics, hormone therapy, and age-related medical conditions, may interact with plasma p-tau217 levels. Shadyab also pointed out that the study focused exclusively on older women, indicating that the findings may not be applicable to men or younger populations. Additionally, the research examined overall dementia outcomes rather than specific subtypes, such as Alzheimer’s disease.

As the understanding of dementia risk factors evolves, the potential for early detection through blood tests like p-tau217 may revolutionize the approach to managing and preventing this debilitating condition.

According to Fox News Digital, the implications of this research could significantly impact future dementia prevention strategies.

Compounds in cannabis, particularly cannabidiol (CBD) and cannabigerol (CBG), may offer new treatment options for metabolic dysfunction-associated steatotic liver disease, a common chronic liver condition affecting many adults worldwide.

Research from the Hebrew University of Jerusalem suggests that compounds found in cannabis could pave the way for innovative treatments for the world’s most prevalent chronic liver disorder. The study, published in the British Journal of Pharmacology, highlights the potential of cannabidiol (CBD) and cannabigerol (CBG) in reducing liver fat and enhancing metabolic health in experimental models.

CBD is the more extensively researched non-intoxicating cannabinoid, while CBG serves as a precursor cannabinoid from which CBD is derived. Unlike THC, the primary psychoactive component of cannabis, both CBD and CBG do not induce a “high,” making them promising candidates for long-term medical applications.

Metabolic dysfunction-associated steatotic liver disease (MASLD) currently impacts approximately one-third of the global adult population, as indicated by health data. This condition is closely associated with obesity and insulin resistance, yet there are few approved pharmaceutical treatments available. Consequently, patients often rely on challenging lifestyle changes to manage their condition.

Lead study author Joseph Tam, director of the Multidisciplinary Center for Cannabinoid Research at Hebrew University, stated, “Our findings identify a new mechanism by which CBD and CBG enhance hepatic energy and lysosomal function.”

The research emphasizes a process known as “metabolic remodeling,” where the cannabis compounds create a “backup battery” for the liver by increasing levels of phosphocreatine, a high-energy molecule stored in muscle cells. This energy reserve enables the liver to function more effectively under the stress of a high-fat diet, an unexpected finding noted by the research team.

Additionally, the study revealed that CBD and CBG restored the activity of “cellular cleaning crews,” known as cathepsins. These enzymes operate within the cell’s recycling centers to break down harmful fats and waste. As a result, the liver became more adept at clearing dangerous lipids, including triglycerides and ceramides, which are known to cause inflammation.

While both CBD and CBG demonstrated effectiveness, CBG yielded more pronounced results in specific areas, such as reducing total body fat mass, lowering “bad” LDL cholesterol, and improving insulin sensitivity. The researchers believe this study opens new avenues for utilizing plant-based compounds to treat metabolic diseases by focusing on cellular energy management and waste disposal.

Despite these promising findings, the research team cautioned that the study was conducted in a controlled experimental setting. Further clinical trials are essential to ascertain the appropriate application of these compounds for human patients.

Recent studies have also raised concerns regarding the use of cannabis as a medical treatment. A major analysis published in JAMA examined over 2,500 scientific papers from the past 15 years, including reviews, clinical trials, and guidelines related to medical marijuana. This review underscored significant discrepancies between public perception and scientific evidence regarding the effectiveness of cannabis for various medical conditions.

The researchers concluded that only a limited number of conditions have clear, well-established benefits from cannabinoid therapies supported by high-quality clinical data. “Whenever a substance is widely used, there is likely to be a very wide set of outcomes,” noted Dr. Alex Dimitriu, who is double board-certified in psychiatry and sleep medicine. He emphasized that this study illustrates the reality that cannabis is not a universal remedy.

The strongest evidence currently supports FDA-approved cannabinoid medications for treating specific conditions, including appetite loss related to HIV/AIDS, chemotherapy-induced nausea and vomiting, and certain severe pediatric seizure disorders.

Individuals interested in exploring marijuana for medical purposes are encouraged to consult with a healthcare provider to discuss potential risks and benefits, ensuring informed decision-making regarding their health.

According to Fox News, the implications of this research could significantly impact the future treatment landscape for liver diseases.

Recent studies indicate that GLP-1 drugs, including Ozempic and Wegovy, may increase fracture risk and osteoporosis in older adults with Type 2 diabetes, prompting calls for closer monitoring of bone health.

A new study suggests that GLP-1 medications, such as Ozempic and Wegovy, may elevate the risk of fractures by 11% in adults aged 65 and older who have Type 2 diabetes, compared to those using other diabetes treatments.

These GLP-1 drugs have revolutionized the management of Type 2 diabetes and obesity, but recent findings indicate that healthcare providers should be more vigilant regarding bone health in older patients prescribed these medications. A study published in February in the Journal of Clinical Endocrinology & Metabolism revealed that older adults with Type 2 diabetes who began using GLP-1 medications experienced a statistically significant increase in the risk of fragility fractures.

Dr. Michal Kasher Meron, an endocrinologist at Meir Medical Center in Israel and the study’s lead author, emphasized that while an 11% increase may seem modest, it is significant for a vulnerable population. “Both older age and Type 2 diabetes are independent risk factors for fragility fractures,” she stated. “This is a population that deserves special attention.”

Fragility fractures are typically caused by minor falls or routine activities and are often associated with osteoporosis. Such fractures can lead to hospitalization, loss of independence, and even increased mortality among older adults, according to Dr. Kasher Meron.

The study monitored over 46,000 adults aged 65 and older for nearly three years. After making necessary adjustments, researchers found that those using GLP-1 medications had a modest but statistically significant increase in fracture risk.

Previous studies involving younger patients using older GLP-1 medications did not indicate an increased fracture risk. However, the newer and more potent versions are now commonly prescribed to older adults, which alters the risk landscape. “In older adults treated with contemporary medications, the fracture risk picture looks different and warrants close attention,” Dr. Kasher Meron noted.

It is important to highlight that the study was observational, indicating an association rather than causation. Researchers could not ascertain whether the increased risk was due to weight loss, dietary changes, muscle loss, or a direct effect on bone health.

Despite these findings, Dr. Kasher Meron advocates for assessing bone health before initiating GLP-1 medications in older patients rather than treating it as an afterthought. The study’s results coincide with additional research presented at the American Academy of Orthopaedic Surgeons’ annual meeting, which raised further concerns regarding bone health.

In an analysis of over 146,000 adults with obesity and Type 2 diabetes, those using GLP-1 medications were found to have a 29% higher relative risk of developing osteoporosis over five years compared to nonusers. Additionally, rates of gout were slightly elevated, affecting 7.4% of GLP-1 users versus 6.6% of nonusers, representing a 12% relative increase. Osteomalacia, a condition characterized by softening of the bones, was rare but occurred approximately twice as often in GLP-1 users, according to the study, which has not yet undergone peer review.

Experts suggest several mechanisms may contribute to these findings. GLP-1 medications suppress appetite and can lead to rapid weight loss, which is known to reduce bone density. This reduction occurs partly because less mechanical load is placed on the skeleton. Dr. John Horneff, an associate professor of orthopedic surgery at the University of Pennsylvania, likened this phenomenon to astronauts experiencing low bone density after extended periods in a zero-gravity environment.

Moreover, a decrease in caloric intake may result in lower consumption of calcium, vitamin D, and protein—nutrients essential for maintaining bone strength. Rapid weight loss can also temporarily elevate uric acid levels, a byproduct of tissue breakdown, potentially explaining the rise in gout cases.

Despite these concerns, experts caution against discouraging the appropriate use of GLP-1 medications, which have demonstrated significant benefits for blood sugar control, weight loss, and cardiovascular risk reduction. In addition to bone density screenings, experts recommend that patients ensure adequate nutrition and engage in resistance training to help preserve muscle and bone during weight loss.

A spokesperson for Novo Nordisk, the manufacturer of GLP-1 medications, stated that the company prioritizes patient safety and collaborates closely with the U.S. Food and Drug Administration (FDA). Liz Skrbkova, head of U.S. media relations for Novo Nordisk, emphasized that the known risks and benefits of these drugs are reflected in the current FDA-approved labeling. She noted that semaglutide, one of the GLP-1 medications, has shown cardiovascular, kidney, and liver benefits when used under medical supervision.

“Osteoporosis is a complex condition that develops over many years as a result of interdependent risk factors,” Skrbkova added.

These findings underscore the need for healthcare providers to closely monitor bone health in older adults prescribed GLP-1 medications, ensuring that the benefits of these treatments are balanced with potential risks.

According to Fox News Digital, the implications of these studies are significant for the management of diabetes and obesity in older populations.

New research suggests that GLP-1 weight-loss drugs may significantly reduce complications after heart attacks by improving blood flow to heart tissue.

Groundbreaking research indicates that a popular class of weight-loss drugs could play a crucial role in preventing life-threatening heart complications by reopening blocked blood vessels following heart attacks. The study, published this week in Nature Communications, was conducted by researchers from the University of Bristol and University College London.

The research identifies a biological signaling pathway involving the brain, gut, and heart, which may explain how GLP-1 drugs—medications that mimic the hormone glucagon-like peptide-1—help protect heart tissue from a condition known as “no-reflow.” This condition occurs when tiny blood vessels within the heart muscle remain constricted even after the main artery has been cleared during emergency treatment.

Dr. Svetlana Mastitskaya, the study’s lead author and a senior lecturer at Bristol Medical School, highlighted the significance of the findings. “In nearly half of all heart attack patients, tiny blood vessels within the heart muscle remain narrowed, even after the main artery is cleared during emergency medical treatment,” she stated in a press release. “This results in a complication known as ‘no-reflow,’ where blood is unable to reach certain parts of the heart tissue.” The lack of blood flow can increase the risk of heart failure and death within a year, but GLP-1 medications may offer a preventive solution.

The study reveals that when the GLP-1 hormone is released in the gut or administered as a medication, it sends signals to the brain. The brain, in turn, signals the heart to activate specific potassium channels in tiny cells known as pericytes. When these channels open, the pericytes relax, allowing small blood vessels, or capillaries, to widen and improve blood flow to the heart muscle.

Using animal models and cellular imaging, the researchers tracked how GLP-1 interacts with heart tissue. They discovered that when potassium channels were removed, the protective effects of the drugs on the heart were lost, confirming the channels’ critical role in this process.

The findings suggest that existing GLP-1 medications, which are already prescribed for type 2 diabetes and obesity, could be repurposed as emergency treatments during or immediately after a heart attack to minimize tissue damage.

However, the researchers acknowledged several limitations in their study, including its reliance on animal models. Clinical trials will be necessary to determine whether the brain-gut-heart pathway operates with the same timing and efficacy in humans. Moreover, while the study emphasizes the drug’s immediate benefits during a heart attack, it does not clarify whether long-term use of the medication provides any pre-existing level of protection.

This research was primarily funded by the British Heart Foundation, underscoring the potential implications for future heart attack treatments.

According to Fox News, the study opens new avenues for understanding how existing medications can be utilized to enhance heart health and reduce complications following cardiac events.

Researchers have discovered that levetiracetam, a decades-old seizure medication, may prevent the progression of Alzheimer’s disease if administered years before symptoms manifest.

A promising breakthrough in Alzheimer’s prevention has emerged from a recent study suggesting that levetiracetam, a medication traditionally used to treat seizures, may help halt the disease’s progression. Originally approved by the FDA in November 1999 under the brand name Keppra, levetiracetam is primarily prescribed for partial-onset seizures in adults, with its use later expanding to include children and various seizure types.

Researchers at Northwestern University have found that levetiracetam can prevent the formation of toxic amyloid beta peptides, which are small protein fragments commonly associated with Alzheimer’s disease. The study, published in Science Translational Medicine, revealed that the medication effectively inhibited the formation of amyloid-beta 42 in both animal models and cultured human neurons. This effect was also observed in post-mortem brain tissue from individuals with Down syndrome, a group at heightened risk for developing Alzheimer’s.

“While many of the Alzheimer’s drugs currently on the market, such as lecanemab and donanemab, are approved to clear existing amyloid plaques, we’ve identified this mechanism that prevents the production of the amyloid-beta 42 peptides and amyloid plaques,” said Jeffrey Savas, the study’s corresponding author and an associate professor of behavioral neurology at Northwestern University Feinberg School of Medicine. “Our new results uncovered new biology while also opening doors for new drug targets.”

Savas explained that the brain is better equipped to avoid the pathways that produce toxic amyloid-beta 42 proteins during younger years. However, as individuals age, this ability diminishes. “This is not a statement of disease; this is just a part of aging. But in brains developing Alzheimer’s, too many neurons go astray, and that’s when you get amyloid-beta 42 production,” he noted. This accumulation can lead to the formation of tau tangles—abnormal clumps of protein inside brain neurons—which can ultimately kill brain cells, trigger neuroinflammation, and result in dementia.

For levetiracetam to serve as an effective Alzheimer’s preventive, high-risk individuals would need to begin treatment “very, very early,” potentially up to 20 years before elevated levels of amyloid-beta 42 are detected. “You couldn’t take this when you already have dementia because the brain has already undergone a number of irreversible changes and a lot of cell death,” Savas cautioned.

The research team also analyzed existing clinical data to assess whether Alzheimer’s patients taking levetiracetam experienced a slower cognitive decline. They found that these patients had a “significant delay” in the time from cognitive decline to death compared to those not on the medication. “Although the magnitude of change was small (on the scale of a few years), this analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” Savas stated.

Looking ahead, the research team aims to recruit individuals with genetic forms of Alzheimer’s for further testing. However, the study does have limitations, including its reliance on animal models and cultured cells, with no human trials conducted to date. As the study was observational, it cannot definitively prove that levetiracetam caused the prevention of toxic brain proteins.

Savas acknowledged that while levetiracetam shows promise, it is not without its drawbacks. The medication breaks down in the body relatively quickly, prompting the research team to work on developing a “better version” that would have a longer duration of action and more effectively target the mechanism responsible for preventing plaque production.

Common side effects of levetiracetam include drowsiness, weakness, dizziness, irritability, headache, loss of appetite, and nasal congestion. The medication has also been associated with potential mood and behavior changes, such as anxiety, depression, agitation, and aggression. In rare cases, it may lead to severe allergic reactions, skin reactions, blood disorders, and suicidal ideation.

Funding for this study was provided by the National Institutes of Health and the Cure Alzheimer’s Fund. For further details, Fox News Digital reached out to both the drug manufacturer and the researchers for additional comments.

Experts caution individuals with diabetes to be vigilant about certain supplements that may adversely affect blood sugar levels and interact with medications.

Health experts are urging individuals with diabetes to exercise caution when considering dietary supplements, as some may pose significant risks by affecting blood sugar levels or interacting negatively with prescribed medications.

Surveys indicate that approximately 75% of U.S. adults have used dietary supplements, with 58% reporting usage within the past 30 days. However, experts emphasize that certain groups, particularly those with diabetes, should be particularly careful.

Dietary supplements encompass a wide range of products, including vitamins, minerals, herbs, amino acids, and probiotics, all designed to fill nutritional gaps and promote overall wellness. Some supplements target specific health functions, such as immune support, muscle recovery, and bone health.

Unlike prescription medications and over-the-counter drugs, dietary supplements are not typically approved by the Food and Drug Administration (FDA) before they hit the market. However, the FDA does regulate these products and can take action against those deemed unsafe or misbranded.

According to the National Institutes of Health (NIH), several supplements may pose serious health risks for individuals with diabetes. Dawn Menning, a registered dietitian and certified diabetes care and education specialist based in California, highlights St. John’s Wort as a supplement to avoid. While it is often marketed as a natural remedy for mild to moderate depression, it can interfere with diabetes medications by altering how the body metabolizes them.

“This can make medications less effective and complicate blood sugar management,” Menning explained. Although some claim that St. John’s Wort can help regulate blood sugar in individuals with type 2 diabetes, the evidence supporting this is limited and mixed.

Menning warns that combining this supplement with insulin or oral diabetes medications may increase the risk of hypoglycemia, a condition characterized by dangerously low blood sugar levels that can lead to dizziness, fatigue, and fainting.

Another supplement of concern is high-dose niacin, which is sometimes used to manage cholesterol levels. However, Menning cautions that it can significantly raise blood sugar levels, making it difficult to maintain an optimal A1c range.

Asian ginseng is often associated with increased energy, focus, and immune health. While it may offer some benefits for individuals with prediabetes and diabetes, there is evidence suggesting that it could lower blood sugar levels when taken alongside diabetes medications.

Jordan Hill, a registered dietitian with Top Nutrition Coaching in Colorado, advises against β-carotene supplementation for people with diabetes. The American Diabetes Association has linked this supplement to increased risks of lung cancer and cardiovascular mortality.

Cinnamon, frequently promoted for diabetes management and weight loss, has shown potential in reducing blood sugar and lowering insulin resistance. However, excessive consumption can lead to hypoglycemia, as well as liver damage due to a compound called coumarin found in cinnamon.

Oral aloe vera is another supplement that has gained popularity for its purported benefits for diabetes and weight loss. However, when combined with diabetes medications, it may cause blood sugar levels to drop too low, increasing the risk of hypoglycemia. Gastrointestinal side effects are also a concern with aloe vera.

Menning notes that for most supplements, there is insufficient evidence to support any beneficial effects on diabetes or its complications. The American Diabetes Standards of Care state that “without underlying deficiency, there are no benefits from herbal or nonherbal (i.e., vitamin or mineral) supplementation for people with diabetes.”

Furthermore, the American Association of Clinical Endocrinology advises caution with all unregulated nutritional supplements due to their inconsistent composition, quality, and potential for harm.

Experts recommend consulting with a healthcare provider before starting any supplement regimen to better understand how it may impact blood sugar levels, medications, or overall diabetes management.

For more information on the risks associated with dietary supplements for people with diabetes, refer to the National Institutes of Health.

A newly discovered virus within gut bacteria may be linked to an increased risk of colorectal cancer, offering new insights into the disease’s development, according to recent research.

Scientists in Denmark have identified a previously unknown virus residing in the gut bacterium Bacteroides fragilis, which may be associated with the development of colorectal cancer. The study, published in *Communications Medicine* earlier this month, reveals that patients diagnosed with colorectal cancer are approximately twice as likely to carry this virus compared to individuals without the disease.

Dr. Flemming Damgaard, PhD, from the Department of Clinical Microbiology at Odense University Hospital and the University of Southern Denmark, emphasized the significance of microorganisms in relation to human health. “These findings highlight the importance of the microorganisms in the gut and their relation to our health,” he stated. “If we want to understand the full picture, we need to look deep into their genetic material.”

For years, medical professionals have noted a higher prevalence of Bacteroides fragilis in colorectal cancer patients. However, since this bacterium is also commonly found in healthy individuals, the reasons for its harmful effects in certain cases remained unclear. This prompted researchers to investigate subtle genetic variations within the bacteria, leading to an unexpected discovery.

“We were very surprised to find a whole virus inside the bacteria from the colorectal cancer patients,” Damgaard remarked. “That was not something we expected when we started our study.”

The identified virus, classified as a bacteriophage, specifically infects bacteria rather than human cells. Notably, this viral type had not been documented prior to this research. The study involved analyzing stool samples from 877 individuals across Europe, the United States, and Asia, revealing that colorectal cancer patients were about twice as likely to carry traces of the virus compared to their cancer-free counterparts.

While the findings indicate a strong statistical association, researchers caution that the study does not establish a causal link between the virus and colorectal cancer. “The major limitation is that we still don’t know why the virus is linked to colorectal cancer,” co-author Ulrik Stenz Justesen explained. “But we are already continuing our research.”

The research team is currently conducting laboratory experiments and animal studies to explore whether the virus influences the behavior of Bacteroides fragilis in a manner that could contribute to cancer development.

Studies have shown that the human body is home to roughly as many microbial cells as human cells, highlighting the intricate relationship between microbes and overall health. “Our understanding of [microbial cells] is still in its infancy,” Damgaard noted. “There are many health-related discoveries to be made in the human microbiota.”

Colorectal cancer ranks among the leading causes of cancer-related deaths globally, according to the World Health Organization. The disease has gained increased visibility due to the deaths of several high-profile individuals, including James Van Der Beek, Catherine O’Hara, Kirstie Alley, Pelé, and Chadwick Boseman, underscoring its impact across various age groups.

While diet and lifestyle factors are significant contributors to colorectal cancer risk, researchers believe that gut bacteria may also play a crucial role. Current screening methods for colorectal cancer include stool tests that detect hidden blood and colonoscopies. In the future, researchers suggest it may be possible to test stool samples for viral markers similar to those identified in this study.

The researchers pointed to cervical cancer as an example of how recognizing a viral cause can enhance prevention efforts. Following the link between HPV and cervical cancer, vaccination programs have significantly reduced new cases. Although it is premature to draw direct comparisons, the researchers remain hopeful that colorectal cancer could follow a similar trajectory if a definitive viral role is established.

“It is too early to act,” Damgaard cautioned. “We have a lot of hope, and that is what we want people to have at this point,” he concluded.

According to Fox News Digital, this research opens new avenues for understanding the complexities of colorectal cancer and the potential role of viruses within the gut microbiome.

James Van Der Beek’s death underscores a troubling rise in colon cancer cases among younger adults, prompting urgent calls for increased awareness and earlier screening.

Following the death of actor James Van Der Beek after a two-and-a-half-year battle with colon cancer, health experts are sounding the alarm about the increasing prevalence of this disease among younger individuals. The star of “Dawson’s Creek” publicly shared his stage 3 colon cancer diagnosis in November 2024, although he was officially diagnosed in August 2023 after undergoing a colonoscopy.

In an August 2025 interview with Healthline, Van Der Beek revealed that the first warning sign of his colon cancer was a change in his bowel movements, which he initially attributed to his coffee consumption. “Before my diagnosis, I didn’t know much about colorectal cancer,” he admitted. “I didn’t even realize the screening age had dropped to 45; I thought it was still 50.”

Recent research has highlighted a concerning trend: colorectal cancer (CRC) has become the leading cause of cancer-related death among men and women aged 50 and younger, according to the American Cancer Society. This marks a significant shift from the 1990s, when CRC was the fifth deadliest cancer in this age group. While overall cancer deaths have declined by approximately 44% since 1990, CRC is the only major cancer that has seen an increase in mortality rates for those under 50 during this time.

Dr. Aparna Parikh, medical director of the Center for Young Adult Colorectal Cancer at the Mass General Cancer Center, noted that the reasons behind this rise remain unclear. “Experts don’t entirely understand why cases are on the rise,” she explained. “But it seems to be an interplay of a person’s risk factors, overall makeup, and early exposures.” These exposures may include dietary habits, environmental factors, and even antibiotic use, along with lifestyle choices.

A recent study by the American Cancer Society found that long-term heavy drinking is associated with an increased risk of developing colorectal cancer. Other significant risk factors include family history of the disease, obesity, smoking, a diet high in red and processed meats, inflammatory bowel disease, and a personal or family history of polyps.

In a recent appearance on “America’s Newsroom,” Fox News senior medical analyst Dr. Marc Siegel discussed the rising incidence of CRC among younger adults. He highlighted the role of genetics and the consumption of ultraprocessed foods, citing a study from Mass General that indicates a diet high in such foods increases the likelihood of colon cancer by 45%. Additionally, a diet rich in processed meats, such as hot dogs, raises the risk by 30%, while a diet high in red meat increases the risk by 20%.

Experts emphasize that while colorectal cancer may not present symptoms in its early stages, certain signs should not be ignored. Dr. Eitan Friedman, Ph.D., an oncologist and founder of The Suzanne Levy-Gertner Oncogenetics Unit at the Sheba Medical Center in Israel, confirmed that changes in bowel habits are a primary red flag for colorectal cancer. Other symptoms include fatigue due to anemia, abdominal pain or discomfort, rectal bleeding, weakness, and unexplained weight loss.

Dr. Erica Barnell, Ph.D., a physician-scientist at Washington University School of Medicine and co-founder of Geneoscopy, noted that Van Der Beek’s experience of having no obvious symptoms is not uncommon. “Many colorectal cancers develop silently, without obvious symptoms,” she explained. “By the time symptoms appear, the disease may already be advanced.”

Early detection is crucial for improving outcomes in colorectal cancer cases. “Colonoscopy at age 45 onwards, at five- to ten-year intervals, has been shown to lead to early detection of polyps that have the potential to become malignant,” Dr. Friedman stated. “Removing these polyps can significantly minimize the risk of malignant transformation.”

Unfortunately, Dr. Barnell pointed out that screening compliance in the United States remains below national targets, with the most significant gaps found in rural, low-income, and minority communities. “Most people don’t like talking about bowel habits, but paying attention to changes can save your life,” she urged. “Screening gives us the chance to find problems early—often before you feel sick—and that can make all the difference.”

Dr. Siegel reiterated the importance of colonoscopies as the most effective method for screening CRC, especially when polyps are detected and removed before they can develop into cancer. The rising incidence of colorectal cancer among younger adults, as exemplified by Van Der Beek’s tragic story, serves as a stark reminder of the need for increased awareness and proactive health measures.

As the conversation around colorectal cancer continues to evolve, it is essential for individuals to stay informed about their health and the importance of early screening. According to the American Cancer Society, understanding risk factors and recognizing warning signs can be life-saving.

James Van Der Beek highlighted a critical warning sign of colorectal cancer months before his passing, emphasizing the importance of early screening at age 45.

James Van Der Beek, the actor best known for his role in “Dawson’s Creek,” shared an important warning sign of his stage 3 colon cancer prior to his death at the age of 48. His wife, Kimberly Van Der Beek, confirmed his passing in a heartfelt social media post on Wednesday.

In November 2024, Van Der Beek received a diagnosis of colorectal cancer, but he had previously expressed to Healthline in August that he had not experienced any alarming symptoms. “There wasn’t any red flag or something glaring,” he stated. Despite maintaining a healthy lifestyle, including cold plunges and excellent cardiovascular fitness, he was unaware of his cancer diagnosis.

The only symptom he did notice was a change in his bowel movements, which he initially attributed to his coffee consumption. “Before my diagnosis, I didn’t know much about colorectal cancer,” Van Der Beek admitted. He was surprised to learn that the recommended screening age had been lowered to 45, believing it was still set at 50.

Ultimately, a colonoscopy revealed that he had stage 3 colon cancer. Professor Eitan Friedman, M.D., Ph.D., an oncologist at the Sheba Medical Center in Israel, confirmed that changes in bowel habits are a primary indicator that should raise suspicion for colorectal cancer. Other symptoms can include fatigue linked to anemia, blood in the stool, weight loss, loss of appetite, and abdominal discomfort.

Dr. Erica Barnell, M.D., Ph.D., a physician-scientist at Washington University School of Medicine and co-founder of Geneoscopy, noted that Van Der Beek’s experience of having no obvious symptoms is not uncommon. “Many colorectal cancers develop silently, without obvious symptoms,” she explained. “By the time symptoms appear, the disease may already be advanced.”

Friedman highlighted that symptoms are particularly concerning for individuals aged 45 and older who have at least one first-degree relative with colon cancer or other gastrointestinal malignancies, as well as those with active inflammatory bowel diseases like ulcerative colitis or Crohn’s disease.

The lifetime risk of developing colorectal cancer for an average-risk individual is estimated to be between 4% and 5%. Friedman emphasized the importance of colonoscopies starting at age 45, recommending them every five to ten years. This approach has been shown to facilitate early detection of polyps that could become malignant, allowing for their removal and significantly reducing the risk of cancer.

Despite the clear benefits of screening, Barnell pointed out that compliance in the U.S. remains below national targets, with the largest gaps found in rural, low-income, and minority communities. To address these disparities, she advocates for improved access to accurate, noninvasive screening technologies and increased public awareness.

“Most people don’t like talking about bowel habits, but paying attention to changes can save your life,” Barnell stressed. “Screening gives us the chance to find problems early — often before you feel sick — and that can make all the difference.”

For more health-related articles, visit www.foxnews.com/health. Fox News Digital previously reached out to Van Der Beek’s representative for comment.

Men are at a significantly higher risk of heart attacks than women, with the threat emerging as early as their mid-30s, according to a new study from Northwestern University.

A recent study conducted by researchers at Northwestern University reveals that men face the risk of heart attacks seven years earlier than women, beginning in their mid-30s. This finding underscores the necessity for earlier cardiovascular screening for men.

The study, published in the Journal of the American Heart Association (JAHA), analyzed data from over 5,000 adults aged 18 to 30, collected from the mid-1980s through 2020. This research was part of the Coronary Artery Risk Development in Young Adults (CARDIA) study.

According to the findings, men reached a 5% incidence of cardiovascular disease—including heart attacks, strokes, and heart failure—around the age of 50, while women did not reach this threshold until approximately age 57. The primary contributor to this disparity was coronary heart disease, which occurs when the blood vessels supplying the heart muscle become narrowed or blocked. Notably, men experienced a 2% incidence of this condition more than a decade earlier than women. In contrast, the risks associated with stroke and heart failure appeared later in life.

The study indicates that men’s risk of developing heart disease begins to rise significantly around age 35 and remains elevated throughout midlife. All participants in the study were under 65 years old at the time of the last follow-up. Current guidelines typically recommend cardiovascular risk assessments starting at age 40, a practice some experts argue may overlook a critical window for early prevention.

Heart disease develops over many years, with early indicators becoming detectable in young adulthood. Senior study author Alexa Freedman, an assistant professor of preventive medicine at Northwestern University Feinberg School of Medicine, emphasized the importance of promoting heart health screenings and preventive measures in young adulthood, particularly for young men.

Freedman stated, “Our findings highlight the importance of promoting heart health screening and prevention in young adulthood, especially for young men.” The researchers advocate for a more comprehensive approach to assessing heart risk, suggesting that it should extend beyond standard measures such as cholesterol and blood pressure to include a wider range of biological and social factors.

Dr. Andrew Freeman, a cardiologist and director of clinical cardiology at National Jewish Health in Denver, commented on the study’s findings, noting that it aligns with existing knowledge that men tend to experience heart attacks and strokes earlier than women. Although the study did not pinpoint the reasons for this predisposition, Freeman suggested that hormonal differences, dietary habits, and levels of physical activity could all contribute.

“The standard American lifestyle makes us all sick, and men seem to be more prone to developing this disease earlier,” Freeman remarked. He further noted that modern exposures to environmental toxins, such as those found in the food supply, as well as air, light, and sound pollution, are associated with an increased risk of heart disease.

Freeman also highlighted that lifestyle factors such as increased sedentary behavior, inadequate sleep, heightened stress levels, and reduced social connections can exacerbate cardiovascular issues. “I think this study is really underscoring that it’s time for some big changes,” he said.

To mitigate heart health risks, Freeman recommends addressing any existing comorbidities, such as high blood pressure, high cholesterol, and obesity. He suggests that individuals at higher risk for cardiovascular events may benefit from earlier screening, although he believes that early preventive measures should be applied universally.

“Coronary disease is manifesting earlier than ever here in the U.S., and we need to do everything we can to clean up our lifestyles and reduce our disease burden,” Freeman concluded. “If you’re a man, you’ve got to be extra aggressive earlier in life.”

These findings highlight the critical need for awareness and proactive measures in heart health, particularly among young men, to combat the rising incidence of cardiovascular disease.

According to Fox News, the study serves as a call to action for both individuals and healthcare providers to prioritize heart health from a younger age.

New research indicates that individuals who identify as “night owls” may face increased risks of heart attack and stroke due to circadian misalignment affecting their cardiovascular health.

Recent findings published in the Journal of the American Heart Association reveal that adults who consider themselves “evening people” tend to have poorer cardiovascular health and a higher risk of heart-related issues. The study examined the relationship between a person’s chronotype—whether they are naturally inclined to be active in the morning or evening—and their overall heart health.

The research analyzed 14 years of data from the UK Biobank, involving approximately 300,000 adults with an average age of 57. According to the study, around 8% of participants identified as “definitely evening people,” meaning they typically stayed up very late. In contrast, 24% classified themselves as “definitely morning people,” who tended to rise and retire early. The remaining 67% fell into an “intermediate” category, expressing uncertainty about their chronotype.

Heart health was assessed using the American Heart Association’s Life’s Essential 8 score, which evaluates various factors including activity levels, diet, blood pressure, cholesterol, nicotine use, sleep patterns, weight management, and blood sugar levels. Dr. Bradley Serwer, an interventional cardiologist and chief medical officer at VitalSolution, explained the significance of this comprehensive assessment.

The researchers also tracked the incidence of heart attacks and strokes during the follow-up period. They found that individuals who were more active in the evening exhibited a 79% higher risk of poor cardiovascular health compared to those in the intermediate group. Additionally, they faced a 16% increased risk of heart attack or stroke. Conversely, those who identified as morning people had slightly better heart health scores, with the effects being more pronounced in women than in men.

Lead study author Sina Kianersi, Ph.D., a research fellow at Brigham and Women’s Hospital and Harvard Medical School, noted that “evening people” often experience circadian misalignment. This misalignment occurs when their internal body clock does not synchronize with the natural light-dark cycle or their daily routines. Kianersi pointed out that evening people may engage in behaviors detrimental to cardiovascular health, such as poor diet, smoking, and irregular sleep patterns.

Dr. Serwer, who was not involved in the study, emphasized the role of lifestyle habits in these findings. “Cardiovascular disease has multiple contributing causes,” he stated. “Sleep is just one variable—and the importance of high-quality, restorative sleep should not be undervalued.” The implications of these findings could guide healthcare providers in developing tailored lifestyle and medical interventions aimed at preventing cardiovascular events.

However, the study does have limitations. It does not establish a causal relationship between staying up late and heart problems but rather indicates an association. Additionally, the research relied on self-reported data regarding schedules, habits, and health, which may introduce bias. The UK Biobank participants are primarily White and generally healthier than the average population, suggesting that the results may not be broadly applicable.

Dr. Serwer added that while quality sleep is crucial, further research is necessary to determine the specific impact of sleep on cardiovascular health.

These findings highlight the importance of understanding how sleep patterns can influence heart health and underscore the need for continued investigation into the relationship between lifestyle choices and cardiovascular outcomes, according to Fox News Digital.

Ritesh Shah, founder of the Ritesh Shah Charitable Pharmacy, has been recognized in the ’50 Most Influential People in Pharmacy’ list for his impactful work in equitable healthcare.

RED BANK, NJ – Healthcare innovator Ritesh Shah has been named one of the ’50 Most Influential People in Pharmacy,’ a prestigious national ranking that honors leaders for their advocacy and service within the pharmacy profession.

Shah is the founder of the Ritesh Shah Charitable Pharmacy, a nonprofit organization dedicated to providing essential medications at no cost to uninsured and underinsured individuals. His work as a community pharmacist has garnered attention for establishing a sustainable and scalable model for equitable healthcare delivery.

In response to his recognition, Shah expressed his gratitude, stating, “I’m deeply honored by this recognition. Pharmacy is ultimately about people—meeting patients where they are and ensuring access to life-saving medications. This work is only possible because of the dedicated partners, volunteers, and communities we serve.”

The ‘Pharmacy50’ ranking highlights professionals who are actively transforming the pharmaceutical landscape. Shah’s initiatives have concentrated on enhancing patient access, ensuring medication affordability, and supporting the long-term viability of independent pharmacies. His leadership has been pivotal in repositioning pharmacists as crucial frontline responders, thereby influencing national policy discussions toward more compassionate healthcare solutions.

Shah’s dedication to public health has redefined the role of independent pharmacies, establishing them as trusted community hubs. His nonprofit initiative is frequently referenced as a benchmark for how mission-driven healthcare can significantly improve patient outcomes on a broad scale.

According to India-West, Shah’s contributions to the field of pharmacy exemplify the impact of community-focused healthcare initiatives.

New research indicates that early introduction of peanuts to infants significantly reduces the risk of developing food allergies, with eggs now being the most common allergen among children.

Recent studies have shifted the longstanding advice regarding peanut consumption in infants, suggesting that early exposure can significantly lower the risk of developing food allergies. A study conducted by the Children’s Hospital of Philadelphia, published in October 2025 in the journal *Pediatrics*, found that introducing peanuts during infancy led to a 27% decrease in peanut allergy diagnoses and a 38% reduction in overall food allergies among children.

Historically, parents were advised to avoid giving peanuts to babies for the first few years of life. However, emerging research supports the idea that introducing peanuts as early as 4 to 11 months can help prevent allergies. This change in perspective stems from the landmark 2015 Learning Early About Peanut Allergy (LEAP) trial, which demonstrated that infants with severe eczema or an egg allergy could reduce their risk of developing a peanut allergy by 81% when exposed to peanuts early.

The updated guidelines from the National Institute of Allergy and Infectious Diseases in 2021 further encouraged parents to introduce peanuts, eggs, and other major food allergens as early as 4 to 6 months, even for children without prior allergic reactions. This shift aims to combat the rising prevalence of food allergies among children.

Dr. Stanislaw Gabryszewski, the first author of the study and an attending physician in the Division of Allergy and Immunology at the Children’s Hospital of Philadelphia, expressed optimism about the findings. “Everyone has been wondering whether these landmark public health interventions have had an impact on reducing rates of IgE-mediated food allergies in the United States,” he stated. “We now have data that suggest the effect of this landmark public health intervention is occurring.”

The study’s authors emphasized the importance of education and advocacy surrounding early food introduction practices. They noted that if these findings are confirmed, they would represent a significant advancement in public health, demonstrating that clinical research, when paired with clear guidelines, can effectively alter the trajectory of childhood food allergies.

While the study provides valuable insights, it is important to note that it only included data up to early 2019 and did not account for the 2021 guidelines promoting the early introduction of multiple allergens. Additionally, the research relied on electronic health records for allergy diagnoses, which may overlook some cases, and did not capture individual feeding patterns. As an observational study, it can only establish associations rather than direct cause-and-effect relationships.

Food allergies can pose serious health risks, with peanut allergies in particular leading to severe, life-threatening reactions such as difficulty breathing, throat swelling, and a dangerous drop in blood pressure. These reactions necessitate immediate treatment with epinephrine, a critical allergy medication.

Despite the encouraging findings, not all parents may feel comfortable adhering to the revised guidelines. Dr. Susan Schuval, chief of the Division of Pediatric Allergy and Immunology at Stony Brook Children’s Hospital, noted, “Not everyone has followed those guidelines, but this is further evidence that this early introduction is effective at preventing food allergies.” She encourages parents to consult with their pediatricians regarding any concerns before introducing potential food allergens to their children.

The evolving understanding of food allergies highlights the importance of ongoing research and communication between healthcare providers and families. As more data emerges, the hope is to further reduce the incidence of food allergies and improve the health outcomes for children.

According to Fox News Digital, the implications of these findings could lead to a broader acceptance of early allergen introduction, ultimately benefiting public health.

Viti Vitamins, co-founded by Dr. Pravesh Saini and Anshika Saini, aims to transform brain and nerve health by offering a proactive approach to chronic migraines through scientifically-backed nutrition.

In a wellness market saturated with generic supplements, Viti Vitamins is carving out a unique identity by addressing a widespread yet often misunderstood issue: chronic migraines and headaches. Founded by neurologist Dr. Pravesh Saini and product strategist Anshika Saini, this Los Angeles-based brand is built on the powerful idea of merging clinical precision with everyday simplicity to support brain and nerve health through consistent, proactive nutrition.

Rather than viewing migraines as mere inconveniences, Viti Vitamins treats them as chronic neurological conditions that require daily care rather than reactive solutions. This innovative perspective is at the core of the brand’s mission.

The inspiration for Viti Vitamins stemmed directly from Dr. Saini’s extensive experience in clinical neurology. After training at Loyola Stritch School of Medicine and completing a Neurology residency and Neurocritical Care subspecialization at the University of Southern California, Dr. Saini spent years treating patients whose lives were disrupted by frequent headaches and migraines.

Over time, he observed a recurring pattern among his patients. “Patients were looking for preventative care, but the market offered fragmented solutions,” Dr. Saini explained. “Most products focused on a single ingredient, like magnesium or B2, forcing people to piece together multiple supplements. It was expensive, confusing, and unsustainable.”

Despite clinical research consistently supporting the role of multiple nutrients in migraine prevention, over-the-counter options rarely reflected that science in a single, reliable product. This disconnect between clinical efficacy and commercial availability became the foundation for Viti Vitamins.

The brand’s debut product, Viti Vitamins Migraine Support Gummies, embodies its commitment to clinical integrity and daily usability. These gummies feature a first-of-its-kind blend of six nutrients commonly recommended by neurologists for migraine support: Magnesium, Vitamin B2, Vitamin B6, CoQ10, Feverfew, and Ginger.

Designed for consistent daily use, the formulation supports healthy nerve function over time rather than providing only temporary relief. Additionally, the product is intentionally clean—vegan, preservative-free, gelatin-free, and devoid of artificial dyes, fillers, sweeteners, and stimulants. Naturally colored with spirulina and sweetened, the gummies are crafted to encourage long-term adherence to the regimen.

Dr. Saini emphasized the importance of user experience, stating, “Our goal was to create something people could trust—and actually enjoy taking. If a product feels like a chore or causes side effects, people won’t stay consistent, no matter how effective it is on paper.”

While Dr. Saini leads the formulation and clinical direction, Anshika Saini oversees strategy, marketing, and brand development, ensuring that scientific rigor translates into an approachable consumer experience. With a background in product management and technology consulting at a Fortune 500 company, Anshika brings a systems-driven mindset to wellness innovation.

“When you’re managing a chronic condition, the last thing you need is a complicated, untrustworthy ritual,” she said. “We wanted to eliminate the guesswork and create a single-dose solution where science and simplicity align.”

For Anshika, Viti Vitamins represents an opportunity to empower individuals to regain control over their health without overwhelming them with jargon, excessive dosing schedules, or inconsistent formulations. Her vision focuses on developing holistic supplements that seamlessly integrate into everyday life, transforming evidence-based care into an effortless daily habit.

Together, Anshika and Dr. Saini exemplify a growing trend in health entrepreneurship: the fusion of medical expertise with consumer-first design. Their approach shifts migraine care from crisis management to long-term neurological wellness.

Rather than promising miracle cures, Viti Vitamins emphasizes integrity, consistency, and sustainability—principles the founders believe are essential for lasting vitality. “Brain and nerve health shouldn’t only be addressed when something goes wrong,” Anshika stated. “It should be supported every day, just like physical fitness or nutrition.”

As awareness around neurological wellness continues to rise, Viti Vitamins positions itself at the intersection of science-backed medicine and modern lifestyle design, offering a proactive solution for individuals seeking support rather than reactive relief.

From formulation to daily operations, the founders share a unified belief: lasting wellness is built through simple, trustworthy routines grounded in real science—not fleeting trends, according to Global Net News.

New research reveals that flu-positive individuals did not transmit the virus to healthy adults during a controlled study, suggesting key factors that may reduce flu transmission.

This year’s flu season has been characterized by an aggressive new strain, leading to record-high hospitalizations and severe symptoms across the United States. As public health officials seek ways to curb the spread of influenza, a groundbreaking study has uncovered several factors that may significantly reduce transmission rates.

Researchers from the University of Maryland Schools of Public Health and Engineering, alongside the School of Medicine in Baltimore, conducted a unique study on influenza transmission. They placed flu-positive college students in a hotel room with healthy middle-aged adult volunteers to observe potential virus spread.

The study, published in the journal PLOS Pathogens, is reportedly the first clinical trial to investigate how the flu spreads from naturally infected individuals to uninfected ones. A total of 11 healthy volunteers participated in the trial, living on a quarantined floor of a Baltimore-area hotel for two weeks. During this period, they engaged in various simulated interactions, including conversations, physical activities like yoga, and sharing objects such as pens and tablets.

Throughout the study, researchers closely monitored the participants for symptoms, conducted daily nasal swabs, and collected saliva and blood samples to test for antibodies. They also measured the “viral exposure” in the volunteers’ breathing air and the ambient air in the activity room. A specialized machine called the Gesundheit II, developed by Dr. Donald Milton and colleagues at Harvard T.H. Chan School of Public Health, was used to assess the exhaled breath of the participants.

At the conclusion of the experiment, none of the healthy individuals contracted the flu, a finding attributed to several factors. Notably, the infected students exhibited minimal coughing, which researchers noted was crucial since they were retaining “a lot of virus in their noses” and only releasing small amounts into the air.

Dr. Jianyu Lai, the study’s lead data analyst, emphasized that coughing is a significant factor in flu transmission. “Our data suggests key things that increase the likelihood of flu transmission — coughing is a major one,” he stated in a press release.

Another important factor identified was the ventilation and air movement within the study room. The air was continuously mixed by a heater and dehumidifier, which diluted the small amounts of virus present in the air. Lai pointed out that middle-aged adults typically exhibit lower susceptibility to influenza compared to younger adults.

Dr. Donald Milton, a professor at the University of Maryland’s Department of Global, Environmental and Occupational Health and an expert in infectious disease aerobiology, noted that most researchers assume airborne transmission is a primary mode of disease spread. “At this time of year, it seems like everyone is catching the flu virus, and yet our study showed no transmission,” he remarked. “What does this say about how flu spreads and how to stop outbreaks?”

Milton, who was among the first experts to identify effective measures to halt the spread of COVID-19, stressed the importance of findings from such trials in updating international infection-control guidelines. “Being up close, face-to-face with other people indoors where the air isn’t moving much, seems to be the most risky thing — and it’s something we all tend to do a lot,” he explained.

He further suggested that portable air purifiers, which can both stir up and clean the air, could be beneficial in reducing transmission risks. However, he cautioned that if individuals are in close proximity and someone is coughing, wearing a mask, particularly an N95, remains the best preventive measure.

According to data from the Centers for Disease Control and Prevention (CDC), approximately 11 million flu illnesses and around 5,000 deaths have been reported so far in the 2025-2026 influenza season. A significant portion of current flu cases is attributed to the new influenza A subclade K variant.

These findings could reshape our understanding of flu transmission and inform public health strategies aimed at mitigating outbreaks in the future, according to Source Name.

The first-ever fentanyl vaccine, designed to prevent overdoses, is set to enter human trials in early 2026 after successful animal studies.

A groundbreaking vaccine aimed at preventing fentanyl overdoses is on track for clinical trials in humans, following promising results from animal studies. This innovative vaccine is designed to block fentanyl from entering the brain, thereby preventing its lethal effects and reducing the risk of overdose. If successful, it would represent the first preventive treatment against fentanyl overdoses, which are a leading cause of drug-related fatalities in the United States.

Unlike existing treatments such as naloxone, which reverse the effects of an overdose after it occurs, this vaccine works proactively by creating antibodies that target fentanyl. The vaccine contains a synthetic fragment of fentanyl linked to a protein known as CRM197, along with an immune-activating compound called dmLT. This combination stimulates the immune system to produce antibodies that capture fentanyl in the bloodstream before it can reach the brain, according to Colin Haile, co-founder and scientific adviser of ARMR Sciences, the biotech company that licensed the vaccine.

“In a vaccinated individual, those anti-fentanyl antibodies are in the blood,” Haile explained. “If they consume fentanyl, the antibodies grab onto the drug and prevent it from getting into the brain. They would feel no effects if they ingest fentanyl — absolutely none. And they would not overdose.” He added that eventually, the fentanyl would be eliminated from the body.

In studies conducted on mice and rats, researchers observed that the animals maintained antibodies against fentanyl for up to six months after vaccination. While some critics have raised concerns that such a vaccine might inadvertently encourage drug use, Haile countered that vaccinated individuals would not experience the euphoric effects typically associated with fentanyl, thus diminishing the incentive for misuse. The primary advantage of the vaccine, he noted, is its potential to mitigate the health risks associated with fentanyl use, particularly respiratory depression, which is the leading cause of death from this potent synthetic opioid.

The initial human clinical trial is scheduled to begin in early 2026 at the Center for Human Drug Research, affiliated with the University of Leiden in the Netherlands. This small Phase 1 trial will enroll approximately 40 participants and will focus on assessing the vaccine’s safety and immune response. Following the Phase 1 trial, a Phase 2 trial will evaluate the vaccine’s effectiveness in blocking fentanyl’s effects in humans.

Currently, the data available is limited to animal models, and it remains uncertain how effective the vaccine will be in humans. However, Haile reported that no adverse side effects were observed in the animal studies, likely due to the fact that the vaccine’s components are proteins that have been previously used in other human applications, establishing a known safety profile. He emphasized that the doses used in the vaccine are extremely low, and even in toxicology studies where animals received doses 20 times higher than what would be administered to humans, no signs of toxicity were detected.

Haile identified several potential use cases for the vaccine, particularly for individuals with opioid use disorder who are seeking to quit using fentanyl. It could also serve as a protective measure for first responders and healthcare workers at risk of accidental exposure to fentanyl. Additionally, military and national security personnel could benefit from the vaccine, as it may offer protection against fentanyl and similar compounds that could be used as chemical threats. Parents of at-risk teens or young adults may also seek the vaccine, given the prevalence of fentanyl being mixed with other substances, such as marijuana.

Looking ahead, Haile expressed optimism that this vaccine could pave the way for the development of other anti-drug vaccines targeting substances like cocaine and methamphetamine, which are already in the pipeline. “If we can tackle the primary ones — fentanyl, cocaine, and methamphetamine — we will be saving hundreds of thousands of lives,” he stated.

Dr. Marc Siegel, senior medical analyst for Fox News, described the vaccine’s progress as a “very exciting advance with a huge upside.” He expressed enthusiasm about the upcoming human trials, noting that the vaccine could significantly reduce the number of overdoses resulting from fentanyl use. “This is likely to prevent many overdoses where a patient is sedated and stops breathing as a result of fentanyl,” Siegel remarked.

While the antidote for fentanyl, known as Narcan, is effective, it has limitations. Fentanyl can remain in the system for many hours, while Narcan, an opioid antagonist, wears off after a few hours and requires re-administration. Siegel cautioned that the vaccine should be targeted toward those truly at risk for opioid overdoses and addiction, as fentanyl also serves important medical purposes, such as pain management for cancer patients and use in anesthesia.

The development of this vaccine has been supported by funding from the U.S. Department of Defense and is licensed to ARMR Sciences, which is working to bring this innovative solution to market.

As the landscape of opioid use and addiction continues to evolve, the potential impact of this vaccine could be transformative, offering a new avenue for prevention and protection against one of the most dangerous substances in circulation today, according to Fox News.

New research indicates that statins significantly reduce death rates and serious cardiovascular events in adults with type 2 diabetes, regardless of their heart disease risk level.

A recent study has revealed that statins, commonly prescribed cholesterol-lowering medications, may provide benefits to a broader range of individuals with type 2 diabetes than previously understood. Researchers found that these drugs not only lower the risk of death but also reduce serious cardiovascular events across all heart-risk categories, including those deemed low-risk based on standard 10-year heart disease predictions.

The research, conducted by scientists at the University of Hong Kong, utilized health records from the IQVIA Medical Research Data, a comprehensive medical database in the U.K. The study focused on adults aged 25 to 84 with type 2 diabetes who did not have serious heart disease or liver issues at the outset. Participants were monitored for up to 10 years, allowing for an extensive analysis of long-term health outcomes.

In the study, researchers compared individuals who initiated statin therapy with those who did not, categorizing patients based on their estimated 10-year risk of developing cardiovascular disease. This approach enabled them to determine whether the benefits of statins were limited to higher-risk patients or applicable to all.

The findings, published in the Annals of Internal Medicine, indicated that adults with type 2 diabetes who were prescribed statins experienced a lower likelihood of dying from any cause and a reduced incidence of major cardiovascular events, such as heart attacks and other serious heart-related complications. Notably, these advantages were evident even among patients classified as low-risk according to standard predictive tools.

Regarding safety, the study reported minimal concerns. A slight increase in muscle-related side effects, known as myopathy, was noted in one risk group; however, there was no significant rise in liver problems, which are often associated with statin use.

The researchers acknowledged that certain health-related factors, such as lifestyle habits, diet, exercise, and adherence to medical advice, were not fully captured in the data. These unmeasured variables could potentially influence the study’s outcomes. Additionally, some hospital events may not have been accurately recorded, suggesting that a few hospitalizations or complications might have been overlooked, which could slightly impact the findings’ accuracy.

Given the study’s results, the researchers recommend that healthcare providers consider the potential benefits of statin therapy for most adults with type 2 diabetes, even when short-term cardiovascular risk appears low. Patients are encouraged to consult with their healthcare professionals before starting or adjusting their statin therapy, as individual health factors, possible side effects, and personal cardiovascular risk should all be taken into account.

According to Fox News, this research underscores the importance of reevaluating treatment strategies for individuals with type 2 diabetes, highlighting the potential for statins to play a crucial role in improving health outcomes across various risk levels.

A recent study reveals that tramadol, a commonly prescribed opioid for chronic pain, offers minimal relief while posing significant cardiovascular risks.

A new analysis published in BMJ Evidence-Based Medicine has found that tramadol, a widely prescribed opioid painkiller, demonstrates limited effectiveness for chronic pain and increases the risk of serious cardiovascular harm.

Tramadol has long been viewed as a safer or less addictive alternative to other opioids, which has contributed to its extensive use in treating chronic pain, according to the study authors. Dr. Marc Siegel, a senior medical analyst for Fox News, noted, “Often, we may use tramadol to avoid more addictive drugs like other opioids, though in fact tramadol is a synthetic opioid. It is much milder.”

The analysis examined data from 19 randomized clinical trials involving 6,506 adults suffering from conditions such as osteoarthritis, chronic low back pain, neuropathic pain, and fibromyalgia. All studies compared tramadol to a placebo treatment.

Overall, the findings indicated that tramadol resulted in a small reduction in pain; however, the relief was less than what is typically deemed clinically meaningful. Alopi M. Patel, M.D., a pain medicine physician at the Icahn School of Medicine at Mt. Sinai in New York City, remarked, “It is notable how minimal the pain reduction was and how clearly the study highlighted the elevated risk of serious adverse events, even over relatively short trial durations.” Patel was not involved in the study.

Participants who received tramadol experienced a higher incidence of adverse events—both serious and non-serious—compared to those given a placebo. Serious adverse events primarily included cardiovascular issues such as chest pain, coronary artery disease, and congestive heart failure. The authors concluded that tramadol likely increases the risk of heart-related complications.

The study’s authors asserted that the benefits of tramadol for chronic pain are minimal, suggesting that the potential harms may outweigh any advantages. This raises significant questions regarding the appropriateness of tramadol for treating chronic pain conditions.

Most of the trials included in the analysis were short-term, with treatment durations ranging from two to 16 weeks and follow-up periods from three to 15 weeks. The researchers acknowledged that this limited their ability to evaluate long-term outcomes.

Furthermore, the authors reported that many outcomes had a high risk of bias, which may have exaggerated the perceived benefits and downplayed the reported harms. Although the trials encompassed various types of chronic pain, the data lacked sufficient detail to draw specific conclusions for individual conditions, making it “harder to generalize the findings to specific patient populations,” according to Patel.

Despite the study’s insights, Dr. Siegel cautioned against interpreting the findings too broadly. He stated, “Looking at slight increased rates of cancer or heart disease among those on the drug is completely misleading, because it is not controlled for other factors and there is no evidence or hint of causation. You would have to first look at underlying characteristics of that group who took the meds.”

He also emphasized that the study did not compare tramadol with stronger opioids like Percocet, which could provide a more comprehensive understanding of its risks and benefits.

Experts advise patients not to discontinue tramadol abruptly, as this can lead to withdrawal symptoms. Those considering changes to their medication regimen should consult their healthcare provider.

Dr. Patel recommended that clinicians and patients engage in transparent, shared decision-making that weighs tramadol’s modest benefits against its risks. “I recommend that clinicians and patients engage in transparent, shared decision-making that considers tramadol’s modest benefits alongside its risks,” he said.

Fox News Digital reached out to several manufacturers of tramadol for comment but did not receive a response.

As the conversation around opioid prescriptions continues, this study underscores the need for careful consideration of the risks associated with tramadol and similar medications in the management of chronic pain.

According to Fox News, the findings of this study may prompt a reevaluation of tramadol’s role in pain management.

The FDA has approved the Wegovy pill, a needle-free weight loss option that may not be effective for everyone, offering an average weight reduction of 16.6%.

The U.S. Food and Drug Administration (FDA) has granted approval for the Wegovy pill, marking the first oral GLP-1 medication designed for weight loss. Developed by Novo Nordisk, this new pill provides a needle-free alternative for individuals seeking to reduce excess body weight, maintain long-term weight loss, and lower the risk of major cardiovascular events.

The approval of the once-daily 25mg semaglutide pill was based on the findings from two significant clinical trials: the OASIS trial program and the SELECT trial. In the OASIS 4 trial, the Wegovy pill demonstrated a mean weight loss of 16.6% among adults who were classified as obese or overweight and had one or more comorbidities. Notably, one in three participants in this trial experienced a weight loss of 20% or more.

According to Novo Nordisk, the weight loss achieved with the Wegovy pill is comparable to that of the injectable version of Wegovy and shares a similar safety profile. Mike Doustdar, president and CEO of Novo Nordisk, expressed optimism about the new treatment option, stating, “With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection.” He emphasized that this oral GLP-1 treatment offers a new, accessible option for individuals dealing with overweight or obesity.

The Wegovy pill is expected to launch in the U.S. in early January 2026. In addition to its approval in the United States, Novo Nordisk has submitted the oral semaglutide for obesity to the European Medicines Agency (EMA) and other regulatory bodies.

Dr. Sue Decotiis, a medical weight-loss specialist based in New York City, confirmed in an interview that studies indicate that oral Wegovy is comparable to the weekly injectable version, minus the need for needles. While the pill may enhance patient compliance and ease of use, Decotiis cautioned that some individuals might not absorb the medication through the gastrointestinal tract as effectively as with the injectable form. This variability can be attributed to individual differences in body chemistry.

Decotiis noted that most side effects associated with the Wegovy pill are expected to be gastrointestinal in nature, similar to those experienced with the injectable version. These may include nausea, vomiting, and constipation.

In her practice, Decotiis has observed that tirzepatide, marketed as Mounjaro and Zepbound, tends to yield greater weight loss and fat loss compared to semaglutide, often by about 20%. This trend has been supported by various studies, which suggest that tirzepatide may also come with fewer side effects.

Looking ahead, Decotiis indicated that more oral GLP-1 medications could be on the horizon in 2026. This includes an Orforglipron application by Lilly and a new combination drug from Novo Nordisk that is pending approval. She expressed optimism about the future of weight loss medications, stating, “There will be more new drugs available in the future that will be more effective for patients who are more insulin-resistant and have not responded as well to semaglutide and/or tirzepatide.” This development is promising, as novel drugs targeting multiple receptors could lead to better long-term outcomes for a broader range of patients.

As these medications become more affordable and accessible, Decotiis stressed the importance of maintaining healthy lifestyle habits. This includes proper nutrition, sufficient protein and fiber intake, and increased hydration, all of which are crucial for achieving lasting weight loss results. “If not, patients will regain weight and could lose muscle and not enough body fat,” she warned.

Fox News Digital reached out to Novo Nordisk for further comments regarding the Wegovy pill.

According to Fox News, the introduction of the Wegovy pill represents a significant advancement in the field of weight management, offering a new option for those struggling with obesity.

FDA has approved Novo Nordisk’s oral weight-loss drug, Wegovy, marking a significant advancement in obesity treatment and patient accessibility.

Novo Nordisk has made a significant breakthrough in the obesity treatment market with the recent approval of its oral weight-loss medication by the U.S. Food and Drug Administration (FDA). This new drug, branded as Wegovy, is the first weight-loss medication to be administered in pill form, offering an alternative to its injectable counterpart.

The FDA’s approval, announced late Monday, is a landmark achievement for Novo Nordisk, as Wegovy is now the first oral weight-loss drug cleared for long-term use. The medication contains 25 mg of semaglutide and is designed to be taken once daily. This new formulation aims to make chronic weight management more accessible for individuals who prefer to avoid injections.

The approval was based on promising results from the OASIS 4 phase-3 clinical trial, which revealed that participants taking the oral Wegovy pill lost, on average, approximately 16.6% of their body weight over a 64-week period. This weight loss significantly surpassed the results seen in the placebo group and is comparable to the efficacy of the weekly injection version of Wegovy.

Additionally, the trial highlighted meaningful reductions in major cardiovascular risk factors alongside the weight loss, further emphasizing the drug’s potential health benefits. Clinicians and public health experts have long recognized the importance of oral formulations, as many patients are reluctant to use injectable medications. Wegovy is expected to retail at around $149 per month and will be available through pharmacies and telehealth partners.

The approval of Wegovy not only represents a clinical advancement but also provides Novo Nordisk with a strategic edge over its competitors, particularly Eli Lilly, which is currently developing its own oral weight-loss therapy, orforglipron. The weight-loss drug market has seen significant growth in recent years, driven by the popularity of GLP-1 receptor agonists and an increasing demand for effective obesity interventions as global rates of obesity continue to rise.

Mike Doustdar, the CEO of Novo Nordisk, who took over the leadership of the company in August, expressed optimism about the new product. He stated, “Patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection.”

The approval of this oral weight-loss therapy underscores the evolving landscape of obesity treatment, where convenience and accessibility are becoming increasingly important. This development reflects a broader shift in healthcare towards long-term, sustainable solutions for chronic health conditions, particularly as obesity presents significant public health challenges worldwide.

Innovations like oral therapies could play a crucial role in improving treatment adherence and patient engagement, ultimately helping to address the growing obesity epidemic. As the market for weight-loss medications continues to expand, the introduction of Wegovy is poised to reshape the way obesity is managed, offering new hope for individuals seeking effective weight-loss solutions.

According to The American Bazaar, the approval of Wegovy marks a pivotal moment in the fight against obesity, highlighting the importance of patient-centered approaches in healthcare.

Stanford researchers have identified two proteins linked to rare heart inflammation following COVID-19 vaccination, providing insights that may help prevent myocarditis, particularly in young males.

Researchers at Stanford University have made significant strides in understanding the rare occurrence of myocarditis, a form of heart inflammation associated with COVID-19 vaccination, particularly among young males. Their findings reveal the role of two specific proteins in triggering this condition.

Myocarditis is a rare side effect of the COVID-19 vaccine, affecting approximately one in 140,000 individuals after the first dose and one in 32,000 after the second dose. The risk is notably higher among males aged 30 and younger, where the incidence rises to one in 16,750. Symptoms of myocarditis can manifest as chest pain, shortness of breath, fever, and palpitations, typically occurring one to three days post-vaccination. Elevated levels of cardiac troponin, a marker indicating heart muscle damage, are also associated with the condition.

According to Dr. Joseph Wu, the director of the Stanford Cardiovascular Institute and a professor of medicine and radiology, most individuals who experience myocarditis recover quickly and regain full heart function. “It’s not a heart attack in the traditional sense,” Wu explained. “There’s no blockage of blood vessels as found in most common heart attacks. When symptoms are mild and the inflammation hasn’t caused structural damage to the heart, we just observe these patients to ensure they recover.” However, he noted that severe cases can lead to hospitalization, critical illness, or even death.

The recent study, conducted in collaboration with The Ohio State University, sought to uncover the underlying mechanisms of myocarditis following vaccination. Researchers analyzed blood samples from vaccinated individuals, comparing those with myocarditis to those without. They discovered that individuals with myocarditis had elevated levels of two proteins—CXCL10 and IFN-gamma—released by immune cells, which contribute to increased inflammation.

“We think these two are the major drivers of myocarditis,” Wu stated. “Your body needs these cytokines to ward off viruses. It’s essential to immune response, but can become toxic in large amounts.” In laboratory models using mice and heart tissue, high concentrations of these proteins resulted in signs of heart irritation similar to mild myocarditis.

One notable finding from the study was the potential to reduce heart damage by specifically blocking these two cytokines without compromising the overall immune response to the vaccine. “This points to a possible future way to prevent or treat myocarditis in people who are at the highest risk, while keeping the benefits of vaccination,” Wu added.

The research team also identified genistein, a natural compound found in soybeans, which demonstrated the ability to reduce inflammation in laboratory tests. However, this compound has yet to be tested in human subjects.

The study’s findings were published in the journal Science Translational Medicine. Dr. Marc Siegel, a senior medical analyst at Fox News, commented on the complexity of the study, emphasizing that myocarditis is rare and the immune mechanisms involved are understandable.

Wu highlighted that myocarditis is significantly more common and severe in individuals infected with COVID-19 compared to those receiving mRNA-based vaccines, with the risk of myocarditis from COVID infection being approximately ten times greater.

The researchers underscored that COVID-19 vaccines have undergone extensive safety scrutiny and have demonstrated an excellent safety record. “mRNA vaccines remain a crucial tool against COVID-19, and this research helps explain a rare side effect and suggests ways to make future vaccines even safer, rather than a reason to avoid vaccination,” Wu stated. He reiterated that the overall benefits of COVID-19 vaccination outweigh the small risk of myocarditis for nearly all groups.

Despite the promising findings, Wu acknowledged limitations in the study, noting that most data were derived from experimental systems involving mice and human cells, which do not fully capture the complexities of myocarditis in real patients. “These findings do not change what people should do right now, because our work is still at the preclinical stage,” he cautioned. “Clinical studies will be needed to confirm whether targeted treatments are safe and effective.”

Wu also pointed out that myocarditis can occur with other vaccines, although symptoms tend to be more diffuse. He remarked on the heightened public awareness surrounding mRNA-based COVID-19 vaccines, stating, “If you get chest pains from a COVID vaccine, you go to the hospital to get checked out, and if the serum troponin is positive, then you get diagnosed with myocarditis. If you get achy muscles or joints from a flu vaccine, you just blow it off.”

The study received funding from the National Institutes of Health and the Gootter-Jensen Foundation, contributing to the ongoing research into vaccine safety and efficacy.

As the scientific community continues to explore the implications of these findings, the focus remains on ensuring the safety of vaccines while maximizing their protective benefits against COVID-19, particularly for vulnerable populations.

According to Fox News, these insights may pave the way for future advancements in vaccine development and myocarditis prevention.

Flu season is intensifying as the new H3N2 variant raises concerns worldwide, prompting health experts to advocate for vaccinations and preventive measures to mitigate severe symptoms.

As flu season approaches, a new strain of the virus is emerging as a significant threat. The Influenza A H3N2 variant, specifically the subclade K variant, has been identified as a key factor in the rising number of cases globally, including in the United States.

Dr. Neil Maniar, a professor of public health practice at Northeastern University in Boston, discussed the early severity of this emerging strain in an interview with Fox News Digital. He noted, “It’s becoming evident that this is a pretty severe variant of the flu.” He emphasized that in regions where this variant has been prevalent, it has led to severe illness, indicating that this flu season is already showing aggressive characteristics.

The subclade K variant appears to differ significantly from previous flu strains, exhibiting heightened versions of common symptoms such as fever, chills, headache, fatigue, cough, sore throat, and runny nose. Dr. Maniar described this variant as the “perfect storm” for a challenging flu season, particularly as vaccination rates are lower this year and the current flu vaccine does not specifically target this strain.

“The vaccine is very important to get, but because it’s not perfectly aligned with this variant, I think that’s also contributing to some degree to the severity of cases we’re seeing,” he explained. “We’re going into this flu season with lower vaccination rates and a variant that in itself seems to be more aggressive.”

Dr. Maniar expressed concern that this flu season could be particularly difficult, both in terms of the total number of cases and the severity of those cases. He pointed out that because subclade K is “quite different” from earlier variants, there is less natural immunity within the community, which further heightens the risk of transmission and severity of illness.

Individuals who are unvaccinated face a greater risk of experiencing more severe symptoms and a higher likelihood of hospitalization, according to Dr. Maniar. He strongly recommends that people take preventive measures, including getting vaccinated and practicing good hygiene.

In addition to vaccination, Dr. Maniar advises frequent and proper handwashing. While the flu can spread through airborne transmission, he noted that various other illnesses, such as norovirus, can survive on surfaces for up to two weeks.

The holiday season also increases the risk of flu transmission, as gatherings, large events, and crowded public transport can expose individuals to others who may be ill. “Those who are not feeling well or exhibiting symptoms should please stay home,” Dr. Maniar urged. “Especially if you think you are in that contagious period of the flu or any of these other illnesses that we’re seeing, whether it’s norovirus or COVID or RSV.”

He added, “If you’re not feeling well, stay home. That’s a great way to recover faster and to ensure that you’re not going to get others around you sick.”

For individuals uncertain about their health status or diagnosis, Dr. Maniar recommends consulting a healthcare provider for testing. Some providers may be able to prescribe medication that can reduce the severity and duration of the illness.

“It’s important that everyone stays vigilant and tries to take care of themselves and their families,” he concluded.

As the flu season unfolds, public health experts continue to stress the importance of vaccinations and preventive measures to combat the spread of this aggressive new variant, ensuring that communities remain safe and healthy.

According to Fox News.

A U.K. man suffered a stroke after consuming eight energy drinks daily, highlighting the serious health risks associated with excessive caffeine intake, according to a recent medical report.

A man in his 50s from the United Kingdom experienced a stroke after drinking eight energy drinks each day, according to a case study published in the journal BMJ Case Reports. The report, authored by doctors at Nottingham University Hospitals, underscores the potential dangers of high caffeine consumption.

The patient, described as “normally fit and well,” presented with symptoms including weakness on his left side, numbness, and ataxia, which is characterized by poor coordination and unsteady walking. Upon seeking medical attention, an MRI confirmed that he had suffered an ischemic thalamic stroke.

Upon his admission to the hospital, the man exhibited elevated blood pressure. Although his blood pressure was managed during treatment, it spiked again after his discharge, despite him taking five different medications to control it. It was later revealed that he was consuming eight cans of energy drinks daily, with each can containing 160 mg of caffeine. Notably, his caffeine intake had not been documented when he was admitted to the hospital.

After the patient ceased his caffeine consumption, his blood pressure returned to normal levels, allowing for the discontinuation of his antihypertensive medications. This case has prompted the authors of the study to raise awareness about the potential risks associated with energy drinks, particularly concerning stroke and cardiovascular health.

Dr. Marc Siegel, a senior medical analyst at Fox News, commented on the case, emphasizing the significant risks tied to high energy drink consumption. “This case report illustrates the high risk associated with a large volume of energy drink consumption, especially because of the high caffeine content, which can raise your blood pressure substantially,” he stated. Dr. Siegel was not involved in the study but highlighted the direct correlation between the man’s excessive caffeine intake and his health crisis.

In light of this incident, the authors of the study advocate for increased public awareness and targeted questioning in clinical practice regarding energy drink consumption. The findings serve as a cautionary tale about the potential health implications of excessive caffeine intake, particularly for individuals who may not recognize the risks associated with energy drinks.

As energy drinks continue to gain popularity, it is crucial for consumers to be aware of their caffeine content and the possible health consequences of overconsumption. The case of this U.K. man serves as a stark reminder of the importance of moderation and the need for greater education on the effects of these beverages.

For more information on health-related topics, readers can refer to various health news sources.

A Michigan man died of rabies after receiving a kidney from a donor who was infected while rescuing a kitten from a skunk, according to a CDC investigation.

A rare case of transplant-related rabies has resulted in the death of a patient in Michigan, following an organ donation from a donor who became infected while saving a kitten from a skunk. The Centers for Disease Control and Prevention (CDC) announced the tragic details of this incident on Thursday.

The unnamed Michigan resident received a kidney from the Idaho donor in December 2024. Unfortunately, the recipient developed severe symptoms that led to hospitalization and invasive medical procedures. The patient experienced fever, tremors, difficulty swallowing, and hydrophobia, which is a fear of water. He succumbed to the disease 51 days after the transplant.

According to the CDC, the donor had contracted rabies from a skunk that exhibited aggressive behavior while he was attempting to rescue a kitten. The investigation revealed that the donor was scratched on the shin by the skunk six weeks prior to his death. The donor’s family reported that he did not believe he had been bitten during the encounter.

“In late October 2024, a skunk approached the donor as he held a kitten in an outbuilding on his rural property,” the CDC stated. “During an encounter that rendered the skunk unconscious, the donor sustained a shin scratch that bled, but he did not think he had been bitten.” The family attributed the skunk’s behavior to its predatory aggression towards the kitten.

Following the encounter, the donor began to experience troubling symptoms, including hallucinations, difficulty swallowing, trouble walking, and a stiff neck. Just two days later, he was found unresponsive at home after a suspected heart attack. Although he was revived at a hospital, he was declared brain-dead and subsequently removed from life support.

The donor’s organs were made available for transplantation after his family documented the skunk encounter in a donor risk assessment. However, health officials noted that the assessment did not include screening for rabies, which is considered rare in humans.

“In the United States, potential donors’ family members often provide information about a donor’s infectious disease risk factors, including animal exposures,” the CDC explained. “Rabies is excluded from routine donor pathogen testing because of its rarity in humans in the United States and the complexity of diagnostic testing.” Initially, the hospital staff treating the donor were unaware of the skunk scratch and attributed his symptoms to existing health conditions.

In addition to the kidney recipient, three other patients received corneal tissue from the same infected donor. These individuals underwent graft removal, received rabies treatment, and remained asymptomatic, according to the CDC.

Health officials have reached out to approximately 370 individuals who may have had contact with the donor. Of those, 46 were advised to undergo rabies post-exposure prophylaxis.

The death of the kidney recipient marks the fourth documented case of rabies transmission through organ transplantation in the United States since 1978. The CDC emphasizes that the risk of such infections remains extremely low.

Transplant teams are now advised to consult with public health officials if a potential donor has recent bites or scratches from animals known to carry rabies, particularly if the donor exhibits unexplained neurological symptoms. However, the CDC noted that “no standard guidance currently exists for addressing reported donor animal exposures by transplant teams.”

Each year, approximately 1.4 million Americans seek care for potential rabies exposure, but fewer than 10 die from the disease due to effective prevention measures, according to the agency. For further details, Fox News Digital reached out to the CDC.

According to Fox News, this incident highlights the need for increased awareness and protocols surrounding organ donation and potential rabies exposure.

Men over 40 face increased health risks, prompting experts to recommend essential medical tests for early detection and prevention of chronic diseases.

As men age, particularly after reaching 40, they become more susceptible to chronic diseases, including heart disease, strokes, and cancer. A survey conducted by the Cleveland Clinic reveals that nearly two-thirds of men admit to delaying doctor visits, often until health issues become severe. Physicians emphasize that routine screenings are crucial for early detection and intervention.

“When it comes to preventing heart attacks, strokes, fatigue, erectile dysfunction, metabolic disease, and early aging, testing is essential,” said Dr. Jack Wolfson, a cardiologist based in Arizona. He urges men to prioritize testing, stating, “If I could give one message to every man over 40: Test, don’t guess. Catch the problem early, fix it naturally, and live to 100 and beyond with vitality.”

Experts recommend several key medical tests that men over 40 should discuss with their healthcare providers. Some of these tests are universally recommended, while others may be more relevant based on individual health factors.

Dr. Andrea Caamano, an endocrinologist from New Jersey, highlights the importance of a complete blood count (CBC) test. This annual blood test assesses the state of red and white blood cells and platelets, providing insights into infections, allergic reactions, inflammation, anemia, and clotting disorders. It is particularly vital for men undergoing testosterone replacement therapy (TRT), as testosterone can influence red blood cell production.

While health agencies like the CDC and the U.S. Preventive Services Task Force (USPSTF) do not recommend routine CBC testing for asymptomatic individuals, they advocate for it in those experiencing symptoms such as anemia, fatigue, or known medical conditions.

Another important test is the comprehensive metabolic panel (CMP), which evaluates metabolic and organ function, including kidney and liver health. Dr. Caamano recommends this test annually for men on TRT, as it can detect issues like liver disease, diabetes, and electrolyte imbalances that may arise with age or medication use.

Routine blood pressure screenings are also crucial, particularly for men aged 40 and older. The CDC and USPSTF recommend annual checks for those with elevated risk factors, as high blood pressure can indicate cardiovascular disease.

Dr. Auda Auda, a physician at Baker Health in New York, emphasizes the significance of a coronary artery calcium (CAC) scan. This test measures calcified plaque in the coronary arteries, providing early insights into cardiovascular health. Auda notes that a high CAC score can lead to targeted lifestyle changes and interventions to prevent heart attacks and strokes.

Dr. Jeremy M. Liff, a neurologist in New York, recommends an advanced lipid profile, which breaks down specific types of LDL cholesterol. This test offers a clearer picture of cardiovascular risk, allowing men to make informed dietary and lifestyle changes to mitigate potential health issues.

Thyroid function testing is another essential component of health screenings for men over 40. This test measures thyroid-stimulating hormone (TSH) levels and can reveal issues that may lead to mood changes, fatigue, or weight fluctuations. Major health organizations recommend this test for individuals at higher risk or those exhibiting symptoms of thyroid dysfunction.

The prostate-specific antigen (PSA) test is critical for screening prostate health. While the USPSTF advises shared decision-making for men aged 55 to 69, it is essential for those at risk of prostate cancer to discuss this test with their healthcare provider.

Additionally, monitoring insulin sensitivity can provide valuable insights into metabolic health. Dr. Liff points out that poor insulin sensitivity is linked to various health issues, including fatty liver disease and cognitive decline. Early detection allows for proactive lifestyle changes to protect long-term health.

Hormonal testing, including testosterone levels, is also recommended for men experiencing symptoms such as low libido or fatigue. Consistency in testing is vital, as testosterone levels fluctuate throughout the day.

Dr. Wolfson identifies omega-3 index testing as a potentially powerful predictor of heart health. Low levels of omega-3 fatty acids are associated with several health conditions, including heart disease and cognitive decline. While major health organizations do not routinely recommend this test for the general population, it may be beneficial for men over 40.

Carotid artery ultrasounds can reveal narrowing that increases stroke risk, making them valuable for high-risk individuals. Regular monitoring can help prevent serious health events.

Screening for colon cancer is also crucial, particularly for men with a family history. The USPSTF recommends screenings starting at age 45, with colonoscopies every ten years unless polyps are found.

Inflammation markers, such as high-sensitivity C-reactive protein (hs-CRP), can indicate underlying health issues. Dr. Wolfson refers to this test as an “inflammation alarm bell,” highlighting its importance in detecting chronic conditions early.

Lastly, vitamin D testing is recommended to assess overall health, as low levels are linked to various diseases. Dr. Wolfson suggests testing twice a year to account for seasonal changes.

Men over 40 should consult their healthcare providers to determine which tests are appropriate for their individual health needs. Early detection and proactive management can significantly improve health outcomes.

For further information on these tests and personalized recommendations, individuals are encouraged to reach out to their doctors.

According to Fox News Digital.

New research indicates that men with “beer bellies” face an increased risk of heart damage, even if they are of normal weight, challenging existing beliefs about cardiovascular health.

A recent study conducted by German researchers has revealed that men with abdominal fat, often referred to as “beer bellies,” may be at a heightened risk for heart damage, even when their overall weight appears normal. This finding raises important questions regarding the health risks associated with excess weight around the midsection.

The study aimed to investigate whether visceral fat—fat stored deep around internal organs—poses a greater threat to heart health than general body fat. Previous research has suggested that fat distribution plays a significant role in cardiovascular disease, but this study sought to provide more concrete evidence.

“Abdominal obesity, characterized by a high waist-to-hip ratio, is associated with more concerning cardiac remodeling patterns than high body mass index (BMI) alone,” stated Dr. Jennifer Erley, the study’s lead author and a radiology resident at University Medical Center Hamburg-Eppendorf, in a press release.

The research involved 2,244 adults aged 46 to 78, none of whom had been diagnosed with heart disease. Each participant underwent high-resolution MRI scans to assess the size, thickness, and volume of the heart’s chambers. In addition, researchers gathered detailed health information, including weight, blood pressure, cholesterol levels, smoking status, and diabetes history.

Rather than relying solely on BMI, which may overlook the location of fat deposits, the researchers utilized waist-to-hip ratio measurements. This method compares the circumference of the waist to that of the hips, providing insight into how much fat is concentrated around the abdomen. A high waist-to-hip ratio indicates the presence of visceral fat, which is metabolically active and linked to inflammation and stress on internal organs.

The findings indicated that men with elevated waist-to-hip ratios exhibited thicker heart muscles and reduced internal chamber volumes. This suggests that while the heart muscle may become bulkier, it holds less blood, thereby increasing the workload on the heart.

“[Abdominal obesity] appears to lead to a potentially pathological form of cardiac remodeling,” Dr. Erley noted.

When assessed using BMI alone, 69% of the male participants and 56% of the female participants were classified as overweight or obese. However, when waist-to-hip ratio was taken into account, the figures rose significantly, with 91% of males and 64% of females meeting the criteria for obesity.

While general obesity based on BMI was more frequently linked to enlarged heart chambers across all participants, abdominal obesity was specifically associated with thickening of the heart muscle and smaller heart chamber volumes. Over time, these structural changes can lead to heart failure and other cardiovascular complications, the researchers cautioned.

These associations remained robust even after accounting for various risk factors such as age, smoking, blood pressure, and other health indicators. Although the same trends were observed in women, the effects were notably more pronounced in men. This may be attributed to the fact that men typically store fat in the abdominal area more readily than women, particularly as they age.

The study’s findings provide valuable insights into why some individuals with normal or slightly elevated BMI develop heart disease, while others with higher weights do not. It underscores the importance of understanding that simply monitoring weight may not fully capture an individual’s heart health risk.

Despite its significant findings, the study does have limitations. It is observational in nature, meaning it identifies patterns but does not establish direct causation. Furthermore, the researchers did not follow participants long enough to determine who might eventually develop heart disease. While waist-to-hip ratio is a useful measure, it is a simplified approach that may not account for all variations in body composition.

The results of this study were presented at the annual meeting of the Radiological Society of North America in Chicago.

Source: Original article

Current lung cancer screening guidelines may overlook 65% of patients, prompting researchers to advocate for universal age-based screening to improve early detection and treatment outcomes.

A new study from Northwestern Medicine reveals that existing lung cancer screening guidelines may be failing to identify a significant number of Americans at risk for the disease. Researchers are calling for a substantial overhaul of these guidelines to enhance early detection.

Published in JAMA Network Open, the study examined nearly 1,000 lung cancer patients treated at Northwestern Medicine between 2018 and 2023. The primary objective was to determine how many of these patients would have qualified for screening under the current recommendations set forth by the U.S. Preventive Services Task Force (USPSTF).

The USPSTF currently advises annual CT scans for adults aged 50 to 80 who have a smoking history of at least 20 pack-years, which equates to one pack of cigarettes daily for 20 years. This recommendation applies to individuals who either currently smoke or have quit within the last 15 years. Alarmingly, only about 35% of those diagnosed with lung cancer met these criteria, indicating that roughly two-thirds of patients were not flagged for testing prior to their diagnosis.

“Not only does that approach miss many patients who had quit smoking in the past or did not quite meet the high-risk criteria, it also misses other patients at risk of lung cancer, such as non-smokers,” said Dr. Luis Herrera, a thoracic surgeon at Orlando Health, in an interview with Fox News Digital.

The study highlights that patients who fell outside the screening guidelines often had adenocarcinoma, the most prevalent type of lung cancer among never-smokers. The research found that those overlooked by the current guidelines were more frequently women, individuals of Asian descent, and people who had never smoked.

In comparing survival outcomes, the study noted a stark difference: patients who did not meet the screening criteria had a median survival of 9.5 years, while those who qualified lived a median of just 4.4 years. This disparity not only reflects differences in tumor biology and the benefits of earlier detection but also underscores the inadequacies of current screening protocols in identifying a broader spectrum of cases that could be treated more effectively.

“The current participation in lung cancer screening for patients who do qualify based on smoking history is quite low,” Dr. Herrera noted, emphasizing that this is likely due to the complexity of the risk-based criteria and the stigma associated with smoking and lung cancer.

To explore an alternative approach, researchers modeled a universal age-based screening strategy, recommending screenings for everyone aged 40 to 85, regardless of smoking history. Under this model, approximately 94% of lung cancers in their study cohort would have been detected. The researchers estimate that such a change could prevent around 26,000 deaths from lung cancer annually, at a cost of about $101,000 per life saved. This figure is significantly more cost-effective than current screening programs for breast or colorectal cancer, which range from $890,000 to $920,000 per life saved.

Despite the potential benefits, Dr. Herrera acknowledged the numerous challenges associated with adopting lung cancer screening on a broader scale. These challenges include a lack of awareness and some healthcare providers not recommending the screening tests. However, he pointed out that the cost of screening is typically covered by most health insurance plans, and many institutions offer discounts for uninsured patients.

Lung cancer remains the leading cause of cancer-related deaths in the United States, claiming more lives each year than colon, prostate, and breast cancers combined. Due to the restrictive eligibility criteria based on smoking history, millions of individuals at risk are never screened.

Researchers from Northwestern Medicine argue that expanding screening criteria to include all adults within a specified age range could help bridge these gaps, particularly for demographics that are often underdiagnosed.

It is important to note that this study was conducted at a single academic center, which may limit the generalizability of its findings to the broader U.S. population. Additionally, the study relied on retrospective data, meaning it cannot definitively prove how the proposed screening model would perform in real-world scenarios. The cost and mortality projections are based on assumptions that could vary depending on the implementation of the screening program. The researchers also acknowledged that they did not fully account for potential downsides of broader screening, such as false positives or unnecessary follow-up procedures.

For patients who do not qualify for lung cancer screening, there are alternative evaluation options available, including heart calcium scores, CT scans, and other imaging techniques that can help assess lung health and identify any suspicious nodules.

Source: Original article

Health experts are raising alarms over the significant rise in adult-onset food allergies, with nearly 50% of adults developing at least one allergy later in life.

In recent years, there has been a concerning trend of adults developing food allergies later in life, leaving health experts puzzled about the reasons behind this sudden increase. A 2019 study published in JAMA revealed that nearly 50% of adults have developed at least one food allergy during adulthood.

Illana Golant, founder and CEO of the Food and Allergy Fund (FAF) based in New York City, shared her personal experience with food allergies, having developed them in her 40s. “That is not fully understood at all or recognized … we don’t know why they’re starting at certain points,” she explained in an interview with Fox News Digital.

Last week, FAF hosted a forum in Washington, D.C., which was attended by notable figures including HHS Secretary Robert F. Kennedy, FDA Chief Martin Makary, and NIH Director Jay Bhattacharya. During the event, health officials and researchers discussed the potential role of gut health microbes in the rise of food allergies.

Makary highlighted the evolving understanding of microbiomes, stating that the intestine hosts over a billion different types of bacteria that typically exist in a balanced state. However, he noted that modern diets, antibiotics, and other environmental factors can disrupt this balance, leading to inflammation and various health issues, potentially including food allergies.

Golant pointed out that certain foods appear to trigger allergic reactions more frequently in adults than in children. “Seafood, shellfish, and tree nuts seem to be proliferating among adults,” she noted, emphasizing the need for further research into this phenomenon.

A 2018 survey published in the Annals of Allergy, Asthma and Immunology identified shellfish as the top allergen among adults. Golant recounted her own experience with anaphylaxis, stating, “If I didn’t know about food allergies, I would have thought I was having a heart attack.” She expressed concern over the rapid increase in food allergies, remarking, “Genetics can’t change so quickly. In a generation, food allergies have skyrocketed.”

According to FAF, approximately one in ten adults is affected by food allergies. Golant described the situation as a “perfect storm” of various environmental triggers, though she acknowledged that the specific causes remain unclear. “We still don’t know which ones and … if there is one primary [trigger], but my guess is that more likely, it is a perfect storm,” she concluded.

Source: Original article

A recent study from Japan suggests that black cumin seed powder may significantly improve cholesterol levels and support metabolic health.

A new study conducted in Japan has revealed that black cumin seed powder can significantly lower levels of bad cholesterol and triglycerides while simultaneously boosting good cholesterol within just eight weeks.

This research highlights the potential health benefits of black cumin, also known as Nigella sativa or black seed. This spice is commonly used in various Middle Eastern and Indian dishes, including curries and naan, and can also be found in some baked goods and spice blends. Additionally, high-antioxidant black seed oil is available as a dietary supplement, often marketed for its ability to support immunity, reduce inflammation, and improve digestive health.

The study, published in the journal Food Science & Nutrition, examined the effects of black cumin on cholesterol levels. Researchers from Osaka, Japan, conducted both laboratory cell tests and a randomized human trial. In the human trial, participants consumed 5 grams of black cumin seed powder daily for eight weeks, with their cholesterol and appetite levels measured before and after the supplementation period.

The results of the trial were promising. Participants experienced a decrease in triglycerides, low-density lipoprotein (LDL), commonly referred to as “bad” cholesterol, and total cholesterol levels. At the same time, there was an increase in high-density lipoprotein (HDL), known as “good” cholesterol. The findings also indicated a significant improvement in hunger levels, suggesting that black cumin may help with appetite control.

The researchers concluded that both in-vitro and human trials demonstrated black cumin’s anti-adipogenic and lipid-lowering effects. They noted, “The study highlights the potential of black cumin seed extract in improving lipid metabolism. These results suggest that black cumin seed may serve as a promising natural agent in obesity-related conditions, although further investigation involving comprehensive metabolic parameters is warranted.”

Theresa Link, a registered dietitian at Virta Health in Nebraska, commented on the study’s findings in an interview with Fox News Digital. She emphasized that cholesterol is “just one piece” of the cardiovascular health puzzle, suggesting that these findings should be viewed in a broader context regarding metabolic health.

Link also referenced a 2021 study that found black seed oil led to greater weight loss in female participants who consumed it daily. These participants reported feeling fuller, which likely contributed to their weight loss success. However, she cautioned that while the short-term results of the current study are promising, the trials lasted only eight weeks. She stated, “Black cumin seed alone isn’t a magic bullet for preventing obesity but may play a supportive role in weight management when combined with an overall healthy lifestyle.”

Moreover, black cumin contains a compound called thymoquinone, which is rich in antioxidants and may offer additional health benefits. Link noted that longer-term studies are necessary to confirm these effects and to understand how Nigella sativa might fit into a broader approach to metabolic and cardiovascular health.

As research continues, black cumin seed may emerge as a valuable component in the quest for improved metabolic health and cholesterol management, but it is essential to consider its role within the context of a balanced diet and healthy lifestyle.

Source: Original article

Experts are investigating the role of gut microbiomes in the rising prevalence of food allergies affecting over 32 million Americans, seeking potential solutions through innovative therapies.

With more than 32 million Americans grappling with food allergies, health advocates and officials are delving into potential root causes, including the role of microbiomes. A recent forum hosted by the Food Allergy Fund (FAF) in Washington, D.C., featured prominent figures such as HHS Secretary Robert F. Kennedy Jr., FDA Chief Martin Makary, and NIH Director Jay Bhattacharya.

In an interview with Fox News Digital, Makary discussed how the function of microbiomes has evolved over time. He explained that the intestine is home to over a billion different types of bacteria, which typically exist in a balanced state. However, he noted that modern diets, antibiotics, and other environmental exposures can disrupt this balance. “That disequilibrium can cause inflammation, it can cause health problems, and it may be implicated in food allergies,” he stated.

Makary emphasized the importance of gut health, asserting that it is central to overall well-being. He pointed out that certain beneficial microbes may be lacking in contemporary populations due to dietary and environmental changes, which could contribute to the increasing incidence of food allergies.

Researchers at Siolta Therapeutics are actively exploring this hypothesis. Their oral microbiome therapy, STMC-103H, has demonstrated promising results in a Phase 2 trial involving 238 newborns with a family history of allergies. Early data suggests that this therapy could reduce the risk of developing food allergies by 77%, indicating that enhancing gut bacteria early in life may prevent allergies from developing altogether. Final results from this study are anticipated in early 2026.

Ilana Golant, founder and CEO of FAF, remarked to Fox News Digital that food allergies might serve as a “canary in the coal mine” for a broader health crisis linked to the microbiome. To further investigate the connection between gut bacteria and various health issues, FAF has launched its Food Allergy Fund Microbiome Collective in New York City. Golant expressed optimism, stating, “Solving allergies could reveal how to prevent and treat a range of diseases — from autoimmune disorders to neurodegeneration — that impact millions of lives.”

Food allergies are a significant public health concern, affecting approximately one in ten adults and one in thirteen children, according to FAF. Alarmingly, someone in the U.S. is treated in the emergency room for a severe allergic reaction every three minutes. Among the most common food allergies are peanut allergies, with emerging research indicating that early introduction of peanuts may significantly reduce the risk of developing allergies in childhood.

During the FAF conference, Secretary Kennedy noted that food allergies, particularly peanut allergies, appear to be much more prevalent among children today than in previous generations. Reflecting on his own childhood, he remarked, “When I was a kid, I never met anyone with a peanut allergy. I had 11 siblings and about 71 first cousins, and I didn’t know a single person in my schools or at any of the camps I went to who had one.”

Kennedy shared a personal perspective, revealing that one of his sons suffers from severe anaphylactic allergies to peanuts, tree nuts, and several other foods. “By the time he was 2 years old, we’d been to the emergency room about 22 times,” he recounted. Initially focused on treatment and safety, Kennedy soon turned his attention to the broader question of why food allergies are becoming increasingly common. “I have five of my seven children with allergies,” he added.

He acknowledged the complexity of the issue, stating, “There may be many causes, or there may be just one — we don’t know yet. But we’re going to study it. We’re going to break that omertà, end the taboo and find out what’s causing it.”

As research continues, the exploration of gut health and its potential impact on food allergies may pave the way for innovative treatments and a deeper understanding of this growing health crisis.

Source: Original article

A New Jersey man’s death has been linked to a tick-borne allergy to red meat, highlighting the dangers of alpha-gal syndrome, according to researchers at UVA Health.

A 47-year-old man from New Jersey has become the first known fatality associated with a tick-borne allergy to red meat, as reported by researchers at UVA Health in Virginia. The man, whose identity has not been disclosed, died last summer just four hours after consuming a hamburger. This incident followed a similar reaction two weeks earlier after he ate steak.

During the earlier episode, the man experienced severe abdominal pain, diarrhea, and vomiting after consuming the steak, according to a press release from UVA Health. Initially, his death was categorized as “sudden unexplained death” until Dr. Thomas Platts-Mills of UVA Health identified it as a fatal allergic reaction.

The allergy in question is known as alpha-gal syndrome (AGS), commonly referred to as “red-meat allergy” or “tick bite meat allergy.” It is triggered by the bite of the Lone Star tick, which is predominantly found in the Southeastern and Eastern United States. The tick’s saliva contains a sugar molecule called alpha-gal, which, once injected into the body, can lead to allergic reactions to certain types of red meat, including pork, beef, rabbit, lamb, and venison, as well as products derived from mammals such as cheese, milk, and gelatin.

Individuals who consume foods containing these allergens may experience serious symptoms within a few hours, although reactions can vary in severity. Common symptoms include rash, nausea, and vomiting after eating red meat. Other potential reactions may involve itchy or scaly skin, swelling of the lips, face, tongue, and throat, as well as wheezing or shortness of breath, according to the Mayo Clinic.

While fatal anaphylaxis is a rare occurrence in severe cases, the New Jersey man’s death marks the first instance attributed to AGS. Dr. Platts-Mills noted that other factors may have contributed to the man’s severe reaction, including a beer he consumed with his hamburger, exposure to ragweed pollen, and recent physical activity.

Dr. Platts-Mills emphasized the importance of public awareness regarding the symptoms of AGS. “Severe abdominal pain occurring three to five hours after eating beef, pork, or lamb should be investigated as a possible episode of anaphylaxis,” he stated. He also cautioned that tick bites that itch for more than a week or larvae of ticks, often referred to as ‘chiggers,’ can increase sensitization to mammalian-derived meat.

Diagnosis of AGS typically requires antibody testing and a clinical examination. Unfortunately, many patients face a lengthy journey to diagnosis, averaging about seven years, according to Dr. Johanna Salzer, a CDC epidemiologist and author of a 2023 report on AGS. “To get diagnosed, they have to have access to an allergist,” Salzer explained. “For many people, there are barriers to obtaining that level of treatment.”

Once diagnosed, individuals may have AGS for life. However, Salzer noted that some patients may see a decrease in their antibody levels over time if they eliminate reactive foods from their diet. Currently, there is no cure for AGS, but physicians can assist patients in managing their symptoms. “Healthcare providers can offer various strategies to alleviate symptoms based on individual reactions,” Salzer said. For those experiencing severe reactions, EpiPens may be prescribed to counteract potential anaphylactic shock.

To prevent tick bites, Salzer recommends using EPA-approved insect repellents containing DEET, picaridin, IR3535, Oil of Lemon Eucalyptus (OLE), para-menthane-diol (PMD), or 2-undecanone when venturing into areas where ticks may be present. Additionally, wearing long-sleeved shirts, long pants, and socks, as well as avoiding grassy, brushy, and wooded areas, can help reduce the risk of bites.

After returning from tick-prone areas, individuals should shower and conduct a thorough check for ticks. Dr. Platts-Mills urged both doctors and patients in regions where Lone Star ticks are prevalent to remain vigilant about the risks associated with AGS. “If they experience unexpected episodes of severe abdominal pain occurring several hours after consuming mammalian meat, they should be evaluated for possible sensitization to the oligosaccharide alpha-gal,” he advised.

As awareness of alpha-gal syndrome continues to grow, health professionals stress the importance of recognizing symptoms and seeking timely medical attention.

Source: Original article

Researchers have developed an innovative drug-delivery implant that may help patients with hard-to-treat bladder cancer avoid surgery and maintain long-term cancer-free status.

In a significant advancement for bladder cancer treatment, researchers have introduced a new drug-delivery implant that could allow patients to avoid bladder removal surgery. This innovative approach targets a challenging form of bladder cancer known as BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).

The experimental drug, TAR-200, has shown promise in clinical trials conducted by Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson. Traditionally, Bacillus Calmette-Guérin (BCG) is the first-line immunotherapy for early-stage bladder cancers. However, for patients whose cancer does not respond to BCG, options have been limited.

TAR-200 is a small device that releases the chemotherapy drug gemcitabine directly into the bladder. The implant is inserted through a simple outpatient procedure that does not require general anesthesia. This method allows for a targeted delivery of the drug, potentially reducing the need for more invasive treatments.

Dr. Sia Daneshmand, director of urologic oncology at Keck Medicine of USC and lead author of the study, emphasized the significance of this new therapy. “Traditionally, these patients have had very limited treatment options. This new therapy is the most effective one reported to date for the most common form of bladder cancer,” he stated in a press release. “The findings of the clinical trial are a breakthrough in how certain types of bladder cancer might be treated, leading to improved outcomes and saved lives.”

Bladder cancer ranks as the fourth most common cancer among men and the eleventh most common among women. According to the Urology Care Foundation, non-muscle-invasive bladder cancer affects the tissue lining the bladder’s inner surface. High-risk NMIBC is particularly concerning due to its higher likelihood of recurrence following treatment.

The study aimed to provide an alternative for patients whose cancer recurred despite standard therapies. Previously, the standard treatment for these patients involved surgical removal of the bladder and surrounding tissues, a procedure that carries significant health risks and can adversely affect quality of life.

In the clinical trial, participants with high-risk NMIBC who did not respond to BCG were divided into groups to test various drug combinations and treatment methods. One group received TAR-200 every three weeks for approximately six months, followed by maintenance treatments every 12 weeks for up to two years.

Among the 85 patients in this group, an impressive 82.4% showed no detectable signs of cancer following treatment. Furthermore, 52.9% remained cancer-free at the one-year mark, with many maintaining their cancer-free status for over two years without the need for additional therapy.

In another group of patients with a less aggressive form of early-stage bladder cancer, early disease-free survival rates were recorded at 85.3% at six months and 81.1% at nine months. Notably, 94% of participants in this group were able to retain their bladders.

The results of the clinical trial were published earlier this year in the Journal of Clinical Oncology. However, researchers caution that this data is still in the mid-stage (Phase 2b) of testing. Larger-scale trials and regulatory reviews will be necessary before TAR-200 can be considered standard care.

As the researchers noted, “Because the study didn’t include a traditional comparison (no randomized control arm), we can’t definitively say how TAR-200 stacks up against other treatments in a fair head-to-head way.” They also pointed out that the patient group studied is a specific subset of those who are BCG-unresponsive and eligible for bladder preservation, which may not represent all bladder cancer cases.

Additionally, the follow-up period remains relatively short, and the number of participants modest. Consequently, the long-term benefits of TAR-200 and its applicability to larger, more diverse populations are still uncertain.

As research continues, the hope is that TAR-200 and similar therapies will provide new avenues for treatment, improving outcomes for patients battling bladder cancer.

Source: Original article

Chronic kidney disease has emerged as the ninth leading cause of death globally, impacting 788 million individuals, according to a recent comprehensive health study.

Chronic kidney disease (CKD) has officially been ranked as the ninth leading cause of death worldwide, with an estimated 788 million people affected globally. This alarming statistic comes from a significant study recently published in the journal The Lancet.

The research was conducted by a collaborative team from NYU Langone Health, the University of Glasgow, and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. The study analyzed the global rise of kidney disease by reviewing 2,230 published papers and health datasets from 133 countries, focusing on diagnoses, mortality rates, and the overall impact of the disease.

From 1990 to 2023, the number of CKD cases surged from 378 million to 788 million, marking the first time the disease has entered the top ten list of the most deadly diseases globally. The findings were part of the Global Burden of Disease 2023 study, which also indicated that approximately 14% of the adult population worldwide suffers from chronic kidney disease.

In 2023 alone, around 1.5 million people died from kidney disease, reflecting an increase of over 6% since 1993. Most individuals identified in the study were in the early stages of the disease, which can often be managed or improved through medication and lifestyle changes before more invasive treatments like dialysis or surgery become necessary.

The research findings were presented at the American Society of Nephrology’s annual Kidney Week conference, and the authors described it as “the most comprehensive estimate of the condition in nearly a decade.”

Chronic kidney disease impairs the kidneys’ ability to filter waste and excess fluid from the bloodstream. While mild cases may not exhibit any symptoms, advanced stages can necessitate dialysis, kidney replacement therapy, or even organ transplants. Additionally, impaired kidney function has been identified as a significant risk factor for heart disease, contributing to approximately 12% of global cardiovascular mortality.

The study identified several key risk factors for developing kidney disease, including high blood sugar, high blood pressure, and elevated body mass index (BMI). Dr. Josef Coresh, M.D., Ph.D., director of NYU Langone’s Optimal Aging Institute, emphasized the urgency of these findings, stating that chronic kidney disease is “common, deadly, and getting worse as a major public health issue.”

Dr. Coresh further noted that these results should prompt policymakers to prioritize CKD alongside other major health concerns such as cancer, heart disease, and mental health issues.

Dr. Morgan Grams, M.D., Ph.D., the Susan and Morris Mark Professor of Medicine at the NYU Grossman School of Medicine and co-lead author of the study, highlighted that chronic kidney disease is often “underdiagnosed and undertreated.” She stressed the importance of increased urine testing to catch the disease early and ensuring that patients have access to affordable therapies once diagnosed.

Recent advancements in medications have shown promise in slowing disease progression and reducing the risks of heart attack, stroke, and heart failure. However, Dr. Grams cautioned that it may take time to observe the global impact of these new treatments.

Dr. Marc Siegel, a senior medical analyst at Fox News, commented on the “dramatic increase” in kidney disease cases, agreeing that the condition is “vastly underestimated and underdiagnosed,” particularly because early stages often lack noticeable symptoms. He explained that the kidneys play a crucial role in filtering waste and managing electrolytes and acid-base balance, making them sensitive to fluctuations in blood pressure and blood flow.

Dr. Siegel noted that conditions such as high blood pressure, obesity, heart disease, and diabetes can significantly affect kidney function, leading to secondary kidney disease and failure. He urged healthcare providers to be more vigilant regarding kidney health and the effects of certain medications on kidney function.

This study received funding from the National Institutes of Health, the Gates Foundation, and the National Kidney Foundation, underscoring the importance of addressing chronic kidney disease as a pressing public health challenge.

Source: Original article

A recent study indicates that treating gum disease may lower cardiovascular risk by 10% annually, highlighting the significant heart health benefits of intensive dental cleanings.

A new study conducted by researchers at University College London (UCL) reveals that treating gum disease can significantly reduce cardiovascular risk. The findings suggest that intensive dental cleanings may provide heart health benefits beyond improving oral hygiene.

The two-year study focused on individuals suffering from periodontitis, a severe form of gum disease. Participants who received intensive treatment, which included a full-mouth deep cleaning and regular follow-ups, exhibited slower thickening and clogging of a major neck artery compared to those who only received routine cleanings. The research was published this month in the European Heart Journal.

In this randomized controlled trial, 135 adults with periodontitis were tracked at UCL’s Eastman Dental Institute. Periodontitis can arise from various factors, including poor oral hygiene, genetics, smoking, and uncontrolled diabetes. At the 12- and 24-month marks, those who underwent intensive deep cleanings showed reduced gum inflammation and fewer bacteria entering their bloodstream. Their arterial health was also notably better than that of participants who received standard scale-and-polish care, which primarily removes plaque and tartar buildup.

Dr. Marco Orlandi, a co-author of the study, noted that participants receiving intensive gum disease treatment experienced a 0.02 millimeter reduction in the thickening of their carotid arteries over the two-year period. “This is a significant result, as even a 0.01 millimeter reduction corresponds to a 10% decrease in cardiovascular disease risk,” Orlandi explained. He emphasized that this suggests participants may have reduced their risk by approximately 10% each year.

Healthcare professionals often monitor the thickness of the carotid artery wall as an early warning sign for clogged arteries, which can lead to heart attacks and strokes. Although this study did not track actual heart events, the observed changes in arterial health and reduced gum inflammation suggest that improved oral health could play a role in combating cardiovascular disease.

Professor John Deanfield, the lead author of the study and director of cardiovascular prevention at UCL, stated, “This is among the most robust evidence to date that oral and cardiovascular health are interconnected.” He added that addressing periodontitis could become a vital strategy in preventing serious heart and brain events, such as heart attacks and strokes.

Another co-author, Professor Francesco D’Aiuto, emphasized the need for medical and dental professionals to collaborate more closely in recognizing and addressing the cardiovascular implications of gum disease. Periodontitis affects approximately 40% of adults worldwide and can lead to symptoms such as bleeding, swelling, and tenderness of the gums, as well as tooth loss if left untreated.

Dr. Catrise Austin, a New York City cosmetic dentist and host of the “Let’s Talk Smiles” podcast, commented on the findings, stating, “Your gums are part of your vascular system. If they’re inflamed and bleeding, your arteries feel it.” Although she was not involved in the study, she believes the results underscore the importance of healthcare providers paying closer attention to their patients’ gum health.

Austin recommends that patients adopt a proactive approach to oral health by brushing twice daily, flossing daily, scheduling regular professional cleanings, quitting smoking, and managing conditions such as diabetes. “These steps not only protect your smile but also lower inflammation that contributes to cardiovascular disease,” she said.

The study was supported by the National Institute for Health and Care Research (NIHR) and the NIHR UCLH Biomedical Research Center, in collaboration with University College London Hospitals NHS Foundation Trust. It adds to a growing body of research linking gum health to overall well-being.

Earlier this year, an analysis of over 500,000 individuals in the U.K. Biobank found that those exhibiting signs of gum disease, such as bleeding or painful gums, were more likely to have multiple chronic conditions, including diabetes, heart disease, and depression. While previous research indicated a correlation between gum disease and higher cardiovascular risk, this study provides evidence that treating gum disease may indeed reduce the likelihood of heart attacks or strokes.

Fox News Digital has reached out to the study’s authors for further comment.

Source: Original article